!Series_title	"Exploring the effects of different sample preparation factors on RNA sequencing"
!Series_geo_accession	"GSE110417"
!Series_status	"Public on Feb 09 2019"
!Series_submission_date	"Feb 09 2018"
!Series_last_update_date	"May 21 2019"
!Series_pubmed_id	"30529531"
!Series_summary	"We investigated the effects of different sample preparation factors on RNA-seq experiments, including RNA concentration, library storage time, and cryopreserved condition, by comparing their sequencing biases, gene expression profiles, and biological function using primary B cell and CD4+ cell blood samples in healthy subjects."
!Series_overall_design	"The effects of RNA concentration, library storage time, and cryopreserved condition for RNA-seq experiments"
!Series_type	"Expression profiling by high throughput sequencing"
!Series_contributor	"Larry,R,Pease"
!Series_contributor	"Yuji,,Zhang"
!Series_sample_id	"GSM2991062 GSM2991063 GSM2991064 GSM2991065 GSM2991066 GSM2991067 GSM2991068 GSM2991069 GSM2991070 GSM2991071 GSM2991072 GSM2991073 GSM2991074 GSM2991075 GSM2991076 GSM2991077 GSM2991078 GSM2991079 GSM2991080 GSM2991081 GSM2991082 GSM2991083 GSM2991084 GSM2991085 GSM2991086 GSM2991087 GSM2991088 GSM2991089 GSM2991090 "
!Series_contact_name	"Yuji,,Zhang"
!Series_contact_email	"yuzhang@som.umaryland.edu"
!Series_contact_phone	"410-706-8523"
!Series_contact_institute	"University of Maryland"
!Series_contact_address	"660 W. Redwood Street"
!Series_contact_city	"Baltimore"
!Series_contact_state	"MD"
!Series_contact_zip/postal_code	"21201"
!Series_contact_country	"USA"
!Series_supplementary_file	"ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE110nnn/GSE110417/suppl/GSE110417_concentration_count.txt.gz"
!Series_supplementary_file	"ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE110nnn/GSE110417/suppl/GSE110417_frozen_count.txt.gz"
!Series_supplementary_file	"ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE110nnn/GSE110417/suppl/GSE110417_time_count.txt.gz"
!Series_platform_id	"GPL11154"
!Series_platform_taxid	"9606"
!Series_sample_taxid	"9606"
!Series_relation	"BioProject: https://www.ncbi.nlm.nih.gov/bioproject/PRJNA433678"
!Series_relation	"SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRP132594"

!Sample_title	"concentration_1 rep1"	"concentration_100 rep1"	"concentration_250 rep1"	"concentration_500 rep1"	"concentration_1 rep2"	"concentration_100 rep 2"	"concentration_100 rep2"	"concentration_500 rep2"	"time_101SR"	"time_101FR"	"time_103SR"	"time_103FR"	"time_104SR"	"time_104FR"	"time_107SR"	"time_107FR"	"time_107SRN"	"time_109SR"	"time_109FR"	"time_110SR"	"time_110FR"	"frozen_501"	"frozen_501f"	"frozen_506"	"frozen_506f"	"frozen_507"	"frozen_507f"	"frozen_510"	"frozen_510f"
!Sample_geo_accession	"GSM2991062"	"GSM2991063"	"GSM2991064"	"GSM2991065"	"GSM2991066"	"GSM2991067"	"GSM2991068"	"GSM2991069"	"GSM2991070"	"GSM2991071"	"GSM2991072"	"GSM2991073"	"GSM2991074"	"GSM2991075"	"GSM2991076"	"GSM2991077"	"GSM2991078"	"GSM2991079"	"GSM2991080"	"GSM2991081"	"GSM2991082"	"GSM2991083"	"GSM2991084"	"GSM2991085"	"GSM2991086"	"GSM2991087"	"GSM2991088"	"GSM2991089"	"GSM2991090"
!Sample_status	"Public on Feb 09 2019"	"Public on Feb 09 2019"	"Public on Feb 09 2019"	"Public on Feb 09 2019"	"Public on Feb 09 2019"	"Public on Feb 09 2019"	"Public on Feb 09 2019"	"Public on Feb 09 2019"	"Public on Feb 09 2019"	"Public on Feb 09 2019"	"Public on Feb 09 2019"	"Public on Feb 09 2019"	"Public on Feb 09 2019"	"Public on Feb 09 2019"	"Public on Feb 09 2019"	"Public on Feb 09 2019"	"Public on Feb 09 2019"	"Public on Feb 09 2019"	"Public on Feb 09 2019"	"Public on Feb 09 2019"	"Public on Feb 09 2019"	"Public on Feb 09 2019"	"Public on Feb 09 2019"	"Public on Feb 09 2019"	"Public on Feb 09 2019"	"Public on Feb 09 2019"	"Public on Feb 09 2019"	"Public on Feb 09 2019"	"Public on Feb 09 2019"
!Sample_submission_date	"Feb 09 2018"	"Feb 09 2018"	"Feb 09 2018"	"Feb 09 2018"	"Feb 09 2018"	"Feb 09 2018"	"Feb 09 2018"	"Feb 09 2018"	"Feb 09 2018"	"Feb 09 2018"	"Feb 09 2018"	"Feb 09 2018"	"Feb 09 2018"	"Feb 09 2018"	"Feb 09 2018"	"Feb 09 2018"	"Feb 09 2018"	"Feb 09 2018"	"Feb 09 2018"	"Feb 09 2018"	"Feb 09 2018"	"Feb 09 2018"	"Feb 09 2018"	"Feb 09 2018"	"Feb 09 2018"	"Feb 09 2018"	"Feb 09 2018"	"Feb 09 2018"	"Feb 09 2018"
!Sample_last_update_date	"Feb 09 2019"	"Feb 09 2019"	"Feb 09 2019"	"Feb 09 2019"	"Feb 09 2019"	"Feb 09 2019"	"Feb 09 2019"	"Feb 09 2019"	"Feb 09 2019"	"Feb 09 2019"	"Feb 09 2019"	"Feb 09 2019"	"Feb 09 2019"	"Feb 09 2019"	"Feb 09 2019"	"Feb 09 2019"	"Feb 09 2019"	"Feb 09 2019"	"Feb 09 2019"	"Feb 09 2019"	"Feb 09 2019"	"Feb 09 2019"	"Feb 09 2019"	"Feb 09 2019"	"Feb 09 2019"	"Feb 09 2019"	"Feb 09 2019"	"Feb 09 2019"	"Feb 09 2019"
!Sample_type	"SRA"	"SRA"	"SRA"	"SRA"	"SRA"	"SRA"	"SRA"	"SRA"	"SRA"	"SRA"	"SRA"	"SRA"	"SRA"	"SRA"	"SRA"	"SRA"	"SRA"	"SRA"	"SRA"	"SRA"	"SRA"	"SRA"	"SRA"	"SRA"	"SRA"	"SRA"	"SRA"	"SRA"	"SRA"
!Sample_channel_count	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"
!Sample_source_name_ch1	"B cell PBL"	"B cell PBL"	"B cell PBL"	"B cell PBL"	"B cell PBL"	"B cell PBL"	"B cell PBL"	"B cell PBL"	"CD4+ PBL"	"CD4+ PBL"	"CD4+ PBL"	"CD4+ PBL"	"CD4+ PBL"	"CD4+ PBL"	"CD4+ PBL"	"CD4+ PBL"	"CD4+ PBL"	"CD4+ PBL"	"CD4+ PBL"	"CD4+ PBL"	"CD4+ PBL"	"CD4+ PBL"	"CD4+ PBL"	"CD4+ PBL"	"CD4+ PBL"	"CD4+ PBL"	"CD4+ PBL"	"CD4+ PBL"	"CD4+ PBL"
!Sample_organism_ch1	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"
!Sample_characteristics_ch1	"cell type: B cell"	"cell type: B cell"	"cell type: B cell"	"cell type: B cell"	"cell type: B cell"	"cell type: B cell"	"cell type: B cell"	"cell type: B cell"	"cell type: CD4+ T cell"	"cell type: CD4+ T cell"	"cell type: CD4+ T cell"	"cell type: CD4+ T cell"	"cell type: CD4+ T cell"	"cell type: CD4+ T cell"	"cell type: CD4+ T cell"	"cell type: CD4+ T cell"	"cell type: CD4+ T cell"	"cell type: CD4+ T cell"	"cell type: CD4+ T cell"	"cell type: CD4+ T cell"	"cell type: CD4+ T cell"	"cell type: CD4+ T cell"	"cell type: CD4+ T cell"	"cell type: CD4+ T cell"	"cell type: CD4+ T cell"	"cell type: CD4+ T cell"	"cell type: CD4+ T cell"	"cell type: CD4+ T cell"	"cell type: CD4+ T cell"
!Sample_characteristics_ch1	"tumor stage: healthy"	"tumor stage: healthy"	"tumor stage: healthy"	"tumor stage: healthy"	"tumor stage: healthy"	"tumor stage: healthy"	"tumor stage: healthy"	"tumor stage: healthy"	"tumor stage: healthy"	"tumor stage: healthy"	"tumor stage: healthy"	"tumor stage: healthy"	"tumor stage: healthy"	"tumor stage: healthy"	"tumor stage: healthy"	"tumor stage: healthy"	"tumor stage: healthy"	"tumor stage: healthy"	"tumor stage: healthy"	"tumor stage: healthy"	"tumor stage: healthy"	"tumor stage: healthy"	"tumor stage: healthy"	"tumor stage: healthy"	"tumor stage: healthy"	"tumor stage: healthy"	"tumor stage: healthy"	"tumor stage: healthy"	"tumor stage: healthy"
!Sample_molecule_ch1	"polyA RNA"	"polyA RNA"	"polyA RNA"	"polyA RNA"	"polyA RNA"	"polyA RNA"	"polyA RNA"	"polyA RNA"	"polyA RNA"	"polyA RNA"	"polyA RNA"	"polyA RNA"	"polyA RNA"	"polyA RNA"	"polyA RNA"	"polyA RNA"	"polyA RNA"	"polyA RNA"	"polyA RNA"	"polyA RNA"	"polyA RNA"	"polyA RNA"	"polyA RNA"	"polyA RNA"	"polyA RNA"	"polyA RNA"	"polyA RNA"	"polyA RNA"	"polyA RNA"
!Sample_extract_protocol_ch1	"Participant recruitment and blood sample collection were conducted using protocols approval by the Mayo Clinic Institutional Review Board (IRB#12-002580 and IRB#13-002293)."	"Participant recruitment and blood sample collection were conducted using protocols approval by the Mayo Clinic Institutional Review Board (IRB#12-002580 and IRB#13-002293)."	"Participant recruitment and blood sample collection were conducted using protocols approval by the Mayo Clinic Institutional Review Board (IRB#12-002580 and IRB#13-002293)."	"Participant recruitment and blood sample collection were conducted using protocols approval by the Mayo Clinic Institutional Review Board (IRB#12-002580 and IRB#13-002293)."	"Participant recruitment and blood sample collection were conducted using protocols approval by the Mayo Clinic Institutional Review Board (IRB#12-002580 and IRB#13-002293)."	"Participant recruitment and blood sample collection were conducted using protocols approval by the Mayo Clinic Institutional Review Board (IRB#12-002580 and IRB#13-002293)."	"Participant recruitment and blood sample collection were conducted using protocols approval by the Mayo Clinic Institutional Review Board (IRB#12-002580 and IRB#13-002293)."	"Participant recruitment and blood sample collection were conducted using protocols approval by the Mayo Clinic Institutional Review Board (IRB#12-002580 and IRB#13-002293)."	"Participant recruitment and blood sample collection were conducted using protocols approval by the Mayo Clinic Institutional Review Board (IRB#12-002580 and IRB#13-002293)."	"Participant recruitment and blood sample collection were conducted using protocols approval by the Mayo Clinic Institutional Review Board (IRB#12-002580 and IRB#13-002293)."	"Participant recruitment and blood sample collection were conducted using protocols approval by the Mayo Clinic Institutional Review Board (IRB#12-002580 and IRB#13-002293)."	"Participant recruitment and blood sample collection were conducted using protocols approval by the Mayo Clinic Institutional Review Board (IRB#12-002580 and IRB#13-002293)."	"Participant recruitment and blood sample collection were conducted using protocols approval by the Mayo Clinic Institutional Review Board (IRB#12-002580 and IRB#13-002293)."	"Participant recruitment and blood sample collection were conducted using protocols approval by the Mayo Clinic Institutional Review Board (IRB#12-002580 and IRB#13-002293)."	"Participant recruitment and blood sample collection were conducted using protocols approval by the Mayo Clinic Institutional Review Board (IRB#12-002580 and IRB#13-002293)."	"Participant recruitment and blood sample collection were conducted using protocols approval by the Mayo Clinic Institutional Review Board (IRB#12-002580 and IRB#13-002293)."	"Participant recruitment and blood sample collection were conducted using protocols approval by the Mayo Clinic Institutional Review Board (IRB#12-002580 and IRB#13-002293)."	"Participant recruitment and blood sample collection were conducted using protocols approval by the Mayo Clinic Institutional Review Board (IRB#12-002580 and IRB#13-002293)."	"Participant recruitment and blood sample collection were conducted using protocols approval by the Mayo Clinic Institutional Review Board (IRB#12-002580 and IRB#13-002293)."	"Participant recruitment and blood sample collection were conducted using protocols approval by the Mayo Clinic Institutional Review Board (IRB#12-002580 and IRB#13-002293)."	"Participant recruitment and blood sample collection were conducted using protocols approval by the Mayo Clinic Institutional Review Board (IRB#12-002580 and IRB#13-002293)."	"Participant recruitment and blood sample collection were conducted using protocols approval by the Mayo Clinic Institutional Review Board (IRB#12-002580 and IRB#13-002293)."	"Participant recruitment and blood sample collection were conducted using protocols approval by the Mayo Clinic Institutional Review Board (IRB#12-002580 and IRB#13-002293)."	"Participant recruitment and blood sample collection were conducted using protocols approval by the Mayo Clinic Institutional Review Board (IRB#12-002580 and IRB#13-002293)."	"Participant recruitment and blood sample collection were conducted using protocols approval by the Mayo Clinic Institutional Review Board (IRB#12-002580 and IRB#13-002293)."	"Participant recruitment and blood sample collection were conducted using protocols approval by the Mayo Clinic Institutional Review Board (IRB#12-002580 and IRB#13-002293)."	"Participant recruitment and blood sample collection were conducted using protocols approval by the Mayo Clinic Institutional Review Board (IRB#12-002580 and IRB#13-002293)."	"Participant recruitment and blood sample collection were conducted using protocols approval by the Mayo Clinic Institutional Review Board (IRB#12-002580 and IRB#13-002293)."	"Participant recruitment and blood sample collection were conducted using protocols approval by the Mayo Clinic Institutional Review Board (IRB#12-002580 and IRB#13-002293)."
!Sample_extract_protocol_ch1	"RNA libraries were prepared for sequencing using standard Illumina protocols"	"RNA libraries were prepared for sequencing using standard Illumina protocols"	"RNA libraries were prepared for sequencing using standard Illumina protocols"	"RNA libraries were prepared for sequencing using standard Illumina protocols"	"RNA libraries were prepared for sequencing using standard Illumina protocols"	"RNA libraries were prepared for sequencing using standard Illumina protocols"	"RNA libraries were prepared for sequencing using standard Illumina protocols"	"RNA libraries were prepared for sequencing using standard Illumina protocols"	"RNA libraries were prepared for sequencing using standard Illumina protocols"	"RNA libraries were prepared for sequencing using standard Illumina protocols"	"RNA libraries were prepared for sequencing using standard Illumina protocols"	"RNA libraries were prepared for sequencing using standard Illumina protocols"	"RNA libraries were prepared for sequencing using standard Illumina protocols"	"RNA libraries were prepared for sequencing using standard Illumina protocols"	"RNA libraries were prepared for sequencing using standard Illumina protocols"	"RNA libraries were prepared for sequencing using standard Illumina protocols"	"RNA libraries were prepared for sequencing using standard Illumina protocols"	"RNA libraries were prepared for sequencing using standard Illumina protocols"	"RNA libraries were prepared for sequencing using standard Illumina protocols"	"RNA libraries were prepared for sequencing using standard Illumina protocols"	"RNA libraries were prepared for sequencing using standard Illumina protocols"	"RNA libraries were prepared for sequencing using standard Illumina protocols"	"RNA libraries were prepared for sequencing using standard Illumina protocols"	"RNA libraries were prepared for sequencing using standard Illumina protocols"	"RNA libraries were prepared for sequencing using standard Illumina protocols"	"RNA libraries were prepared for sequencing using standard Illumina protocols"	"RNA libraries were prepared for sequencing using standard Illumina protocols"	"RNA libraries were prepared for sequencing using standard Illumina protocols"	"RNA libraries were prepared for sequencing using standard Illumina protocols"
!Sample_taxid_ch1	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"
!Sample_description	"concentration_count.txt"	"concentration_count.txt"	"concentration_count.txt"	"concentration_count.txt"	"concentration_count.txt"	"concentration_count.txt"	"concentration_count.txt"	"concentration_count.txt"	"time_count.txt"	"time_count.txt"	"time_count.txt"	"time_count.txt"	"time_count.txt"	"time_count.txt"	"time_count.txt"	"time_count.txt"	"time_count.txt"	"time_count.txt"	"time_count.txt"	"time_count.txt"	"time_count.txt"	"frozen_count.txt"	"frozen_count.txt"	"frozen_count.txt"	"frozen_count.txt"	"frozen_count.txt"	"frozen_count.txt"	"frozen_count.txt"	"frozen_count.txt"
!Sample_data_processing	"Blood was drawn into sodium heparin tubes (APP Pharmaceuticals, NDC 63323-540-11); CD4+ and B cells were isolated from whole blood using anti-CD4/B microbeads (Miltenyi Biotec) and MS column purification as per the manufacturer’s instructions. A small portion of the cell isolate was set aside for flow cytometry using anti CD3 APC-H7 and anti CD4/B PE-Cy7 (BD PharMingen) to assess purity. Isolated cells were re-suspended at 1 million/ml in RPMI containing 10 % FBS and either immediately lysed in 0.7 ml QIAzol lysis reagent (Qiagen) or incubated for 4 h at 37 °C with 25 μl/ml anti-CD3/antiCD28 Human T-Activator Dynabeads (Invitrogen) prior to lysis. Lysates were stored at −80 °C until processing for RNAseq."	"Blood was drawn into sodium heparin tubes (APP Pharmaceuticals, NDC 63323-540-11); CD4+ and B cells were isolated from whole blood using anti-CD4/B microbeads (Miltenyi Biotec) and MS column purification as per the manufacturer’s instructions. A small portion of the cell isolate was set aside for flow cytometry using anti CD3 APC-H7 and anti CD4/B PE-Cy7 (BD PharMingen) to assess purity. Isolated cells were re-suspended at 1 million/ml in RPMI containing 10 % FBS and either immediately lysed in 0.7 ml QIAzol lysis reagent (Qiagen) or incubated for 4 h at 37 °C with 25 μl/ml anti-CD3/antiCD28 Human T-Activator Dynabeads (Invitrogen) prior to lysis. Lysates were stored at −80 °C until processing for RNAseq."	"Blood was drawn into sodium heparin tubes (APP Pharmaceuticals, NDC 63323-540-11); CD4+ and B cells were isolated from whole blood using anti-CD4/B microbeads (Miltenyi Biotec) and MS column purification as per the manufacturer’s instructions. A small portion of the cell isolate was set aside for flow cytometry using anti CD3 APC-H7 and anti CD4/B PE-Cy7 (BD PharMingen) to assess purity. Isolated cells were re-suspended at 1 million/ml in RPMI containing 10 % FBS and either immediately lysed in 0.7 ml QIAzol lysis reagent (Qiagen) or incubated for 4 h at 37 °C with 25 μl/ml anti-CD3/antiCD28 Human T-Activator Dynabeads (Invitrogen) prior to lysis. Lysates were stored at −80 °C until processing for RNAseq."	"Blood was drawn into sodium heparin tubes (APP Pharmaceuticals, NDC 63323-540-11); CD4+ and B cells were isolated from whole blood using anti-CD4/B microbeads (Miltenyi Biotec) and MS column purification as per the manufacturer’s instructions. A small portion of the cell isolate was set aside for flow cytometry using anti CD3 APC-H7 and anti CD4/B PE-Cy7 (BD PharMingen) to assess purity. Isolated cells were re-suspended at 1 million/ml in RPMI containing 10 % FBS and either immediately lysed in 0.7 ml QIAzol lysis reagent (Qiagen) or incubated for 4 h at 37 °C with 25 μl/ml anti-CD3/antiCD28 Human T-Activator Dynabeads (Invitrogen) prior to lysis. Lysates were stored at −80 °C until processing for RNAseq."	"Blood was drawn into sodium heparin tubes (APP Pharmaceuticals, NDC 63323-540-11); CD4+ and B cells were isolated from whole blood using anti-CD4/B microbeads (Miltenyi Biotec) and MS column purification as per the manufacturer’s instructions. A small portion of the cell isolate was set aside for flow cytometry using anti CD3 APC-H7 and anti CD4/B PE-Cy7 (BD PharMingen) to assess purity. Isolated cells were re-suspended at 1 million/ml in RPMI containing 10 % FBS and either immediately lysed in 0.7 ml QIAzol lysis reagent (Qiagen) or incubated for 4 h at 37 °C with 25 μl/ml anti-CD3/antiCD28 Human T-Activator Dynabeads (Invitrogen) prior to lysis. Lysates were stored at −80 °C until processing for RNAseq."	"Blood was drawn into sodium heparin tubes (APP Pharmaceuticals, NDC 63323-540-11); CD4+ and B cells were isolated from whole blood using anti-CD4/B microbeads (Miltenyi Biotec) and MS column purification as per the manufacturer’s instructions. A small portion of the cell isolate was set aside for flow cytometry using anti CD3 APC-H7 and anti CD4/B PE-Cy7 (BD PharMingen) to assess purity. Isolated cells were re-suspended at 1 million/ml in RPMI containing 10 % FBS and either immediately lysed in 0.7 ml QIAzol lysis reagent (Qiagen) or incubated for 4 h at 37 °C with 25 μl/ml anti-CD3/antiCD28 Human T-Activator Dynabeads (Invitrogen) prior to lysis. Lysates were stored at −80 °C until processing for RNAseq."	"Blood was drawn into sodium heparin tubes (APP Pharmaceuticals, NDC 63323-540-11); CD4+ and B cells were isolated from whole blood using anti-CD4/B microbeads (Miltenyi Biotec) and MS column purification as per the manufacturer’s instructions. A small portion of the cell isolate was set aside for flow cytometry using anti CD3 APC-H7 and anti CD4/B PE-Cy7 (BD PharMingen) to assess purity. Isolated cells were re-suspended at 1 million/ml in RPMI containing 10 % FBS and either immediately lysed in 0.7 ml QIAzol lysis reagent (Qiagen) or incubated for 4 h at 37 °C with 25 μl/ml anti-CD3/antiCD28 Human T-Activator Dynabeads (Invitrogen) prior to lysis. Lysates were stored at −80 °C until processing for RNAseq."	"Blood was drawn into sodium heparin tubes (APP Pharmaceuticals, NDC 63323-540-11); CD4+ and B cells were isolated from whole blood using anti-CD4/B microbeads (Miltenyi Biotec) and MS column purification as per the manufacturer’s instructions. A small portion of the cell isolate was set aside for flow cytometry using anti CD3 APC-H7 and anti CD4/B PE-Cy7 (BD PharMingen) to assess purity. Isolated cells were re-suspended at 1 million/ml in RPMI containing 10 % FBS and either immediately lysed in 0.7 ml QIAzol lysis reagent (Qiagen) or incubated for 4 h at 37 °C with 25 μl/ml anti-CD3/antiCD28 Human T-Activator Dynabeads (Invitrogen) prior to lysis. Lysates were stored at −80 °C until processing for RNAseq."	"Blood was drawn into sodium heparin tubes (APP Pharmaceuticals, NDC 63323-540-11); CD4+ and B cells were isolated from whole blood using anti-CD4/B microbeads (Miltenyi Biotec) and MS column purification as per the manufacturer’s instructions. A small portion of the cell isolate was set aside for flow cytometry using anti CD3 APC-H7 and anti CD4/B PE-Cy7 (BD PharMingen) to assess purity. Isolated cells were re-suspended at 1 million/ml in RPMI containing 10 % FBS and either immediately lysed in 0.7 ml QIAzol lysis reagent (Qiagen) or incubated for 4 h at 37 °C with 25 μl/ml anti-CD3/antiCD28 Human T-Activator Dynabeads (Invitrogen) prior to lysis. Lysates were stored at −80 °C until processing for RNAseq."	"Blood was drawn into sodium heparin tubes (APP Pharmaceuticals, NDC 63323-540-11); CD4+ and B cells were isolated from whole blood using anti-CD4/B microbeads (Miltenyi Biotec) and MS column purification as per the manufacturer’s instructions. A small portion of the cell isolate was set aside for flow cytometry using anti CD3 APC-H7 and anti CD4/B PE-Cy7 (BD PharMingen) to assess purity. Isolated cells were re-suspended at 1 million/ml in RPMI containing 10 % FBS and either immediately lysed in 0.7 ml QIAzol lysis reagent (Qiagen) or incubated for 4 h at 37 °C with 25 μl/ml anti-CD3/antiCD28 Human T-Activator Dynabeads (Invitrogen) prior to lysis. Lysates were stored at −80 °C until processing for RNAseq."	"Blood was drawn into sodium heparin tubes (APP Pharmaceuticals, NDC 63323-540-11); CD4+ and B cells were isolated from whole blood using anti-CD4/B microbeads (Miltenyi Biotec) and MS column purification as per the manufacturer’s instructions. A small portion of the cell isolate was set aside for flow cytometry using anti CD3 APC-H7 and anti CD4/B PE-Cy7 (BD PharMingen) to assess purity. Isolated cells were re-suspended at 1 million/ml in RPMI containing 10 % FBS and either immediately lysed in 0.7 ml QIAzol lysis reagent (Qiagen) or incubated for 4 h at 37 °C with 25 μl/ml anti-CD3/antiCD28 Human T-Activator Dynabeads (Invitrogen) prior to lysis. Lysates were stored at −80 °C until processing for RNAseq."	"Blood was drawn into sodium heparin tubes (APP Pharmaceuticals, NDC 63323-540-11); CD4+ and B cells were isolated from whole blood using anti-CD4/B microbeads (Miltenyi Biotec) and MS column purification as per the manufacturer’s instructions. A small portion of the cell isolate was set aside for flow cytometry using anti CD3 APC-H7 and anti CD4/B PE-Cy7 (BD PharMingen) to assess purity. Isolated cells were re-suspended at 1 million/ml in RPMI containing 10 % FBS and either immediately lysed in 0.7 ml QIAzol lysis reagent (Qiagen) or incubated for 4 h at 37 °C with 25 μl/ml anti-CD3/antiCD28 Human T-Activator Dynabeads (Invitrogen) prior to lysis. Lysates were stored at −80 °C until processing for RNAseq."	"Blood was drawn into sodium heparin tubes (APP Pharmaceuticals, NDC 63323-540-11); CD4+ and B cells were isolated from whole blood using anti-CD4/B microbeads (Miltenyi Biotec) and MS column purification as per the manufacturer’s instructions. A small portion of the cell isolate was set aside for flow cytometry using anti CD3 APC-H7 and anti CD4/B PE-Cy7 (BD PharMingen) to assess purity. Isolated cells were re-suspended at 1 million/ml in RPMI containing 10 % FBS and either immediately lysed in 0.7 ml QIAzol lysis reagent (Qiagen) or incubated for 4 h at 37 °C with 25 μl/ml anti-CD3/antiCD28 Human T-Activator Dynabeads (Invitrogen) prior to lysis. Lysates were stored at −80 °C until processing for RNAseq."	"Blood was drawn into sodium heparin tubes (APP Pharmaceuticals, NDC 63323-540-11); CD4+ and B cells were isolated from whole blood using anti-CD4/B microbeads (Miltenyi Biotec) and MS column purification as per the manufacturer’s instructions. A small portion of the cell isolate was set aside for flow cytometry using anti CD3 APC-H7 and anti CD4/B PE-Cy7 (BD PharMingen) to assess purity. Isolated cells were re-suspended at 1 million/ml in RPMI containing 10 % FBS and either immediately lysed in 0.7 ml QIAzol lysis reagent (Qiagen) or incubated for 4 h at 37 °C with 25 μl/ml anti-CD3/antiCD28 Human T-Activator Dynabeads (Invitrogen) prior to lysis. Lysates were stored at −80 °C until processing for RNAseq."	"Blood was drawn into sodium heparin tubes (APP Pharmaceuticals, NDC 63323-540-11); CD4+ and B cells were isolated from whole blood using anti-CD4/B microbeads (Miltenyi Biotec) and MS column purification as per the manufacturer’s instructions. A small portion of the cell isolate was set aside for flow cytometry using anti CD3 APC-H7 and anti CD4/B PE-Cy7 (BD PharMingen) to assess purity. Isolated cells were re-suspended at 1 million/ml in RPMI containing 10 % FBS and either immediately lysed in 0.7 ml QIAzol lysis reagent (Qiagen) or incubated for 4 h at 37 °C with 25 μl/ml anti-CD3/antiCD28 Human T-Activator Dynabeads (Invitrogen) prior to lysis. Lysates were stored at −80 °C until processing for RNAseq."	"Blood was drawn into sodium heparin tubes (APP Pharmaceuticals, NDC 63323-540-11); CD4+ and B cells were isolated from whole blood using anti-CD4/B microbeads (Miltenyi Biotec) and MS column purification as per the manufacturer’s instructions. A small portion of the cell isolate was set aside for flow cytometry using anti CD3 APC-H7 and anti CD4/B PE-Cy7 (BD PharMingen) to assess purity. Isolated cells were re-suspended at 1 million/ml in RPMI containing 10 % FBS and either immediately lysed in 0.7 ml QIAzol lysis reagent (Qiagen) or incubated for 4 h at 37 °C with 25 μl/ml anti-CD3/antiCD28 Human T-Activator Dynabeads (Invitrogen) prior to lysis. Lysates were stored at −80 °C until processing for RNAseq."	"Blood was drawn into sodium heparin tubes (APP Pharmaceuticals, NDC 63323-540-11); CD4+ and B cells were isolated from whole blood using anti-CD4/B microbeads (Miltenyi Biotec) and MS column purification as per the manufacturer’s instructions. A small portion of the cell isolate was set aside for flow cytometry using anti CD3 APC-H7 and anti CD4/B PE-Cy7 (BD PharMingen) to assess purity. Isolated cells were re-suspended at 1 million/ml in RPMI containing 10 % FBS and either immediately lysed in 0.7 ml QIAzol lysis reagent (Qiagen) or incubated for 4 h at 37 °C with 25 μl/ml anti-CD3/antiCD28 Human T-Activator Dynabeads (Invitrogen) prior to lysis. Lysates were stored at −80 °C until processing for RNAseq."	"Blood was drawn into sodium heparin tubes (APP Pharmaceuticals, NDC 63323-540-11); CD4+ and B cells were isolated from whole blood using anti-CD4/B microbeads (Miltenyi Biotec) and MS column purification as per the manufacturer’s instructions. A small portion of the cell isolate was set aside for flow cytometry using anti CD3 APC-H7 and anti CD4/B PE-Cy7 (BD PharMingen) to assess purity. Isolated cells were re-suspended at 1 million/ml in RPMI containing 10 % FBS and either immediately lysed in 0.7 ml QIAzol lysis reagent (Qiagen) or incubated for 4 h at 37 °C with 25 μl/ml anti-CD3/antiCD28 Human T-Activator Dynabeads (Invitrogen) prior to lysis. Lysates were stored at −80 °C until processing for RNAseq."	"Blood was drawn into sodium heparin tubes (APP Pharmaceuticals, NDC 63323-540-11); CD4+ and B cells were isolated from whole blood using anti-CD4/B microbeads (Miltenyi Biotec) and MS column purification as per the manufacturer’s instructions. A small portion of the cell isolate was set aside for flow cytometry using anti CD3 APC-H7 and anti CD4/B PE-Cy7 (BD PharMingen) to assess purity. Isolated cells were re-suspended at 1 million/ml in RPMI containing 10 % FBS and either immediately lysed in 0.7 ml QIAzol lysis reagent (Qiagen) or incubated for 4 h at 37 °C with 25 μl/ml anti-CD3/antiCD28 Human T-Activator Dynabeads (Invitrogen) prior to lysis. Lysates were stored at −80 °C until processing for RNAseq."	"Blood was drawn into sodium heparin tubes (APP Pharmaceuticals, NDC 63323-540-11); CD4+ and B cells were isolated from whole blood using anti-CD4/B microbeads (Miltenyi Biotec) and MS column purification as per the manufacturer’s instructions. A small portion of the cell isolate was set aside for flow cytometry using anti CD3 APC-H7 and anti CD4/B PE-Cy7 (BD PharMingen) to assess purity. Isolated cells were re-suspended at 1 million/ml in RPMI containing 10 % FBS and either immediately lysed in 0.7 ml QIAzol lysis reagent (Qiagen) or incubated for 4 h at 37 °C with 25 μl/ml anti-CD3/antiCD28 Human T-Activator Dynabeads (Invitrogen) prior to lysis. Lysates were stored at −80 °C until processing for RNAseq."	"Blood was drawn into sodium heparin tubes (APP Pharmaceuticals, NDC 63323-540-11); CD4+ and B cells were isolated from whole blood using anti-CD4/B microbeads (Miltenyi Biotec) and MS column purification as per the manufacturer’s instructions. A small portion of the cell isolate was set aside for flow cytometry using anti CD3 APC-H7 and anti CD4/B PE-Cy7 (BD PharMingen) to assess purity. Isolated cells were re-suspended at 1 million/ml in RPMI containing 10 % FBS and either immediately lysed in 0.7 ml QIAzol lysis reagent (Qiagen) or incubated for 4 h at 37 °C with 25 μl/ml anti-CD3/antiCD28 Human T-Activator Dynabeads (Invitrogen) prior to lysis. Lysates were stored at −80 °C until processing for RNAseq."	"Blood was drawn into sodium heparin tubes (APP Pharmaceuticals, NDC 63323-540-11); CD4+ and B cells were isolated from whole blood using anti-CD4/B microbeads (Miltenyi Biotec) and MS column purification as per the manufacturer’s instructions. A small portion of the cell isolate was set aside for flow cytometry using anti CD3 APC-H7 and anti CD4/B PE-Cy7 (BD PharMingen) to assess purity. Isolated cells were re-suspended at 1 million/ml in RPMI containing 10 % FBS and either immediately lysed in 0.7 ml QIAzol lysis reagent (Qiagen) or incubated for 4 h at 37 °C with 25 μl/ml anti-CD3/antiCD28 Human T-Activator Dynabeads (Invitrogen) prior to lysis. Lysates were stored at −80 °C until processing for RNAseq."	"Blood was drawn into sodium heparin tubes (APP Pharmaceuticals, NDC 63323-540-11); CD4+ and B cells were isolated from whole blood using anti-CD4/B microbeads (Miltenyi Biotec) and MS column purification as per the manufacturer’s instructions. A small portion of the cell isolate was set aside for flow cytometry using anti CD3 APC-H7 and anti CD4/B PE-Cy7 (BD PharMingen) to assess purity. Isolated cells were re-suspended at 1 million/ml in RPMI containing 10 % FBS and either immediately lysed in 0.7 ml QIAzol lysis reagent (Qiagen) or incubated for 4 h at 37 °C with 25 μl/ml anti-CD3/antiCD28 Human T-Activator Dynabeads (Invitrogen) prior to lysis. Lysates were stored at −80 °C until processing for RNAseq."	"Blood was drawn into sodium heparin tubes (APP Pharmaceuticals, NDC 63323-540-11); CD4+ and B cells were isolated from whole blood using anti-CD4/B microbeads (Miltenyi Biotec) and MS column purification as per the manufacturer’s instructions. A small portion of the cell isolate was set aside for flow cytometry using anti CD3 APC-H7 and anti CD4/B PE-Cy7 (BD PharMingen) to assess purity. Isolated cells were re-suspended at 1 million/ml in RPMI containing 10 % FBS and either immediately lysed in 0.7 ml QIAzol lysis reagent (Qiagen) or incubated for 4 h at 37 °C with 25 μl/ml anti-CD3/antiCD28 Human T-Activator Dynabeads (Invitrogen) prior to lysis. Lysates were stored at −80 °C until processing for RNAseq."	"Blood was drawn into sodium heparin tubes (APP Pharmaceuticals, NDC 63323-540-11); CD4+ and B cells were isolated from whole blood using anti-CD4/B microbeads (Miltenyi Biotec) and MS column purification as per the manufacturer’s instructions. A small portion of the cell isolate was set aside for flow cytometry using anti CD3 APC-H7 and anti CD4/B PE-Cy7 (BD PharMingen) to assess purity. Isolated cells were re-suspended at 1 million/ml in RPMI containing 10 % FBS and either immediately lysed in 0.7 ml QIAzol lysis reagent (Qiagen) or incubated for 4 h at 37 °C with 25 μl/ml anti-CD3/antiCD28 Human T-Activator Dynabeads (Invitrogen) prior to lysis. Lysates were stored at −80 °C until processing for RNAseq."	"Blood was drawn into sodium heparin tubes (APP Pharmaceuticals, NDC 63323-540-11); CD4+ and B cells were isolated from whole blood using anti-CD4/B microbeads (Miltenyi Biotec) and MS column purification as per the manufacturer’s instructions. A small portion of the cell isolate was set aside for flow cytometry using anti CD3 APC-H7 and anti CD4/B PE-Cy7 (BD PharMingen) to assess purity. Isolated cells were re-suspended at 1 million/ml in RPMI containing 10 % FBS and either immediately lysed in 0.7 ml QIAzol lysis reagent (Qiagen) or incubated for 4 h at 37 °C with 25 μl/ml anti-CD3/antiCD28 Human T-Activator Dynabeads (Invitrogen) prior to lysis. Lysates were stored at −80 °C until processing for RNAseq."	"Blood was drawn into sodium heparin tubes (APP Pharmaceuticals, NDC 63323-540-11); CD4+ and B cells were isolated from whole blood using anti-CD4/B microbeads (Miltenyi Biotec) and MS column purification as per the manufacturer’s instructions. A small portion of the cell isolate was set aside for flow cytometry using anti CD3 APC-H7 and anti CD4/B PE-Cy7 (BD PharMingen) to assess purity. Isolated cells were re-suspended at 1 million/ml in RPMI containing 10 % FBS and either immediately lysed in 0.7 ml QIAzol lysis reagent (Qiagen) or incubated for 4 h at 37 °C with 25 μl/ml anti-CD3/antiCD28 Human T-Activator Dynabeads (Invitrogen) prior to lysis. Lysates were stored at −80 °C until processing for RNAseq."	"Blood was drawn into sodium heparin tubes (APP Pharmaceuticals, NDC 63323-540-11); CD4+ and B cells were isolated from whole blood using anti-CD4/B microbeads (Miltenyi Biotec) and MS column purification as per the manufacturer’s instructions. A small portion of the cell isolate was set aside for flow cytometry using anti CD3 APC-H7 and anti CD4/B PE-Cy7 (BD PharMingen) to assess purity. Isolated cells were re-suspended at 1 million/ml in RPMI containing 10 % FBS and either immediately lysed in 0.7 ml QIAzol lysis reagent (Qiagen) or incubated for 4 h at 37 °C with 25 μl/ml anti-CD3/antiCD28 Human T-Activator Dynabeads (Invitrogen) prior to lysis. Lysates were stored at −80 °C until processing for RNAseq."	"Blood was drawn into sodium heparin tubes (APP Pharmaceuticals, NDC 63323-540-11); CD4+ and B cells were isolated from whole blood using anti-CD4/B microbeads (Miltenyi Biotec) and MS column purification as per the manufacturer’s instructions. A small portion of the cell isolate was set aside for flow cytometry using anti CD3 APC-H7 and anti CD4/B PE-Cy7 (BD PharMingen) to assess purity. Isolated cells were re-suspended at 1 million/ml in RPMI containing 10 % FBS and either immediately lysed in 0.7 ml QIAzol lysis reagent (Qiagen) or incubated for 4 h at 37 °C with 25 μl/ml anti-CD3/antiCD28 Human T-Activator Dynabeads (Invitrogen) prior to lysis. Lysates were stored at −80 °C until processing for RNAseq."
!Sample_data_processing	"RNA integrity values of  ≥7.0 by Agilent Bioanalyzer (Santa Clara, CA) were processed by the Mayo Clinic Medical Genome Facility Gene Expression Core into TruSeq libraries according to the manufacturer’s instructions (RNA Prep Kit v2, Illumina, San Diego, CA) and published elsewhere [25]. Paired-end DNA adaptors (Illumina) with a single “T” base overhang at the 3’end were immediately ligated to the “A-tailed” cDNA population. Unique indexes, included in the standard TruSeq Kits (12-Set A and 12-Set B), were incorporated at the adaptor ligation step for multiplex sample loading on the flow cells. Libraries (8–10 pM) were loaded onto paired-end flow cells to generate cluster densities of 700,000/mm2 following Illumina’s standard protocol for cBot and cBot paired-end cluster kit version 3. The flow cells were sequenced as 51 X 2 paired-end reads on an Illumina HiSeq 2000 using TruSeq SBS sequencing kit version 3 and HCS v2.0.12 data collection software. Base-calling was performed using RTA version 1.17.21.3."	"RNA integrity values of  ≥7.0 by Agilent Bioanalyzer (Santa Clara, CA) were processed by the Mayo Clinic Medical Genome Facility Gene Expression Core into TruSeq libraries according to the manufacturer’s instructions (RNA Prep Kit v2, Illumina, San Diego, CA) and published elsewhere [25]. Paired-end DNA adaptors (Illumina) with a single “T” base overhang at the 3’end were immediately ligated to the “A-tailed” cDNA population. Unique indexes, included in the standard TruSeq Kits (12-Set A and 12-Set B), were incorporated at the adaptor ligation step for multiplex sample loading on the flow cells. Libraries (8–10 pM) were loaded onto paired-end flow cells to generate cluster densities of 700,000/mm2 following Illumina’s standard protocol for cBot and cBot paired-end cluster kit version 3. The flow cells were sequenced as 51 X 2 paired-end reads on an Illumina HiSeq 2000 using TruSeq SBS sequencing kit version 3 and HCS v2.0.12 data collection software. Base-calling was performed using RTA version 1.17.21.3."	"RNA integrity values of  ≥7.0 by Agilent Bioanalyzer (Santa Clara, CA) were processed by the Mayo Clinic Medical Genome Facility Gene Expression Core into TruSeq libraries according to the manufacturer’s instructions (RNA Prep Kit v2, Illumina, San Diego, CA) and published elsewhere [25]. Paired-end DNA adaptors (Illumina) with a single “T” base overhang at the 3’end were immediately ligated to the “A-tailed” cDNA population. Unique indexes, included in the standard TruSeq Kits (12-Set A and 12-Set B), were incorporated at the adaptor ligation step for multiplex sample loading on the flow cells. Libraries (8–10 pM) were loaded onto paired-end flow cells to generate cluster densities of 700,000/mm2 following Illumina’s standard protocol for cBot and cBot paired-end cluster kit version 3. The flow cells were sequenced as 51 X 2 paired-end reads on an Illumina HiSeq 2000 using TruSeq SBS sequencing kit version 3 and HCS v2.0.12 data collection software. Base-calling was performed using RTA version 1.17.21.3."	"RNA integrity values of  ≥7.0 by Agilent Bioanalyzer (Santa Clara, CA) were processed by the Mayo Clinic Medical Genome Facility Gene Expression Core into TruSeq libraries according to the manufacturer’s instructions (RNA Prep Kit v2, Illumina, San Diego, CA) and published elsewhere [25]. Paired-end DNA adaptors (Illumina) with a single “T” base overhang at the 3’end were immediately ligated to the “A-tailed” cDNA population. Unique indexes, included in the standard TruSeq Kits (12-Set A and 12-Set B), were incorporated at the adaptor ligation step for multiplex sample loading on the flow cells. Libraries (8–10 pM) were loaded onto paired-end flow cells to generate cluster densities of 700,000/mm2 following Illumina’s standard protocol for cBot and cBot paired-end cluster kit version 3. The flow cells were sequenced as 51 X 2 paired-end reads on an Illumina HiSeq 2000 using TruSeq SBS sequencing kit version 3 and HCS v2.0.12 data collection software. Base-calling was performed using RTA version 1.17.21.3."	"RNA integrity values of  ≥7.0 by Agilent Bioanalyzer (Santa Clara, CA) were processed by the Mayo Clinic Medical Genome Facility Gene Expression Core into TruSeq libraries according to the manufacturer’s instructions (RNA Prep Kit v2, Illumina, San Diego, CA) and published elsewhere [25]. Paired-end DNA adaptors (Illumina) with a single “T” base overhang at the 3’end were immediately ligated to the “A-tailed” cDNA population. Unique indexes, included in the standard TruSeq Kits (12-Set A and 12-Set B), were incorporated at the adaptor ligation step for multiplex sample loading on the flow cells. Libraries (8–10 pM) were loaded onto paired-end flow cells to generate cluster densities of 700,000/mm2 following Illumina’s standard protocol for cBot and cBot paired-end cluster kit version 3. The flow cells were sequenced as 51 X 2 paired-end reads on an Illumina HiSeq 2000 using TruSeq SBS sequencing kit version 3 and HCS v2.0.12 data collection software. Base-calling was performed using RTA version 1.17.21.3."	"RNA integrity values of  ≥7.0 by Agilent Bioanalyzer (Santa Clara, CA) were processed by the Mayo Clinic Medical Genome Facility Gene Expression Core into TruSeq libraries according to the manufacturer’s instructions (RNA Prep Kit v2, Illumina, San Diego, CA) and published elsewhere [25]. Paired-end DNA adaptors (Illumina) with a single “T” base overhang at the 3’end were immediately ligated to the “A-tailed” cDNA population. Unique indexes, included in the standard TruSeq Kits (12-Set A and 12-Set B), were incorporated at the adaptor ligation step for multiplex sample loading on the flow cells. Libraries (8–10 pM) were loaded onto paired-end flow cells to generate cluster densities of 700,000/mm2 following Illumina’s standard protocol for cBot and cBot paired-end cluster kit version 3. The flow cells were sequenced as 51 X 2 paired-end reads on an Illumina HiSeq 2000 using TruSeq SBS sequencing kit version 3 and HCS v2.0.12 data collection software. Base-calling was performed using RTA version 1.17.21.3."	"RNA integrity values of  ≥7.0 by Agilent Bioanalyzer (Santa Clara, CA) were processed by the Mayo Clinic Medical Genome Facility Gene Expression Core into TruSeq libraries according to the manufacturer’s instructions (RNA Prep Kit v2, Illumina, San Diego, CA) and published elsewhere [25]. Paired-end DNA adaptors (Illumina) with a single “T” base overhang at the 3’end were immediately ligated to the “A-tailed” cDNA population. Unique indexes, included in the standard TruSeq Kits (12-Set A and 12-Set B), were incorporated at the adaptor ligation step for multiplex sample loading on the flow cells. Libraries (8–10 pM) were loaded onto paired-end flow cells to generate cluster densities of 700,000/mm2 following Illumina’s standard protocol for cBot and cBot paired-end cluster kit version 3. The flow cells were sequenced as 51 X 2 paired-end reads on an Illumina HiSeq 2000 using TruSeq SBS sequencing kit version 3 and HCS v2.0.12 data collection software. Base-calling was performed using RTA version 1.17.21.3."	"RNA integrity values of  ≥7.0 by Agilent Bioanalyzer (Santa Clara, CA) were processed by the Mayo Clinic Medical Genome Facility Gene Expression Core into TruSeq libraries according to the manufacturer’s instructions (RNA Prep Kit v2, Illumina, San Diego, CA) and published elsewhere [25]. Paired-end DNA adaptors (Illumina) with a single “T” base overhang at the 3’end were immediately ligated to the “A-tailed” cDNA population. Unique indexes, included in the standard TruSeq Kits (12-Set A and 12-Set B), were incorporated at the adaptor ligation step for multiplex sample loading on the flow cells. Libraries (8–10 pM) were loaded onto paired-end flow cells to generate cluster densities of 700,000/mm2 following Illumina’s standard protocol for cBot and cBot paired-end cluster kit version 3. The flow cells were sequenced as 51 X 2 paired-end reads on an Illumina HiSeq 2000 using TruSeq SBS sequencing kit version 3 and HCS v2.0.12 data collection software. Base-calling was performed using RTA version 1.17.21.3."	"RNA integrity values of  ≥7.0 by Agilent Bioanalyzer (Santa Clara, CA) were processed by the Mayo Clinic Medical Genome Facility Gene Expression Core into TruSeq libraries according to the manufacturer’s instructions (RNA Prep Kit v2, Illumina, San Diego, CA) and published elsewhere [25]. Paired-end DNA adaptors (Illumina) with a single “T” base overhang at the 3’end were immediately ligated to the “A-tailed” cDNA population. Unique indexes, included in the standard TruSeq Kits (12-Set A and 12-Set B), were incorporated at the adaptor ligation step for multiplex sample loading on the flow cells. Libraries (8–10 pM) were loaded onto paired-end flow cells to generate cluster densities of 700,000/mm2 following Illumina’s standard protocol for cBot and cBot paired-end cluster kit version 3. The flow cells were sequenced as 51 X 2 paired-end reads on an Illumina HiSeq 2000 using TruSeq SBS sequencing kit version 3 and HCS v2.0.12 data collection software. Base-calling was performed using RTA version 1.17.21.3."	"RNA integrity values of  ≥7.0 by Agilent Bioanalyzer (Santa Clara, CA) were processed by the Mayo Clinic Medical Genome Facility Gene Expression Core into TruSeq libraries according to the manufacturer’s instructions (RNA Prep Kit v2, Illumina, San Diego, CA) and published elsewhere [25]. Paired-end DNA adaptors (Illumina) with a single “T” base overhang at the 3’end were immediately ligated to the “A-tailed” cDNA population. Unique indexes, included in the standard TruSeq Kits (12-Set A and 12-Set B), were incorporated at the adaptor ligation step for multiplex sample loading on the flow cells. Libraries (8–10 pM) were loaded onto paired-end flow cells to generate cluster densities of 700,000/mm2 following Illumina’s standard protocol for cBot and cBot paired-end cluster kit version 3. The flow cells were sequenced as 51 X 2 paired-end reads on an Illumina HiSeq 2000 using TruSeq SBS sequencing kit version 3 and HCS v2.0.12 data collection software. Base-calling was performed using RTA version 1.17.21.3."	"RNA integrity values of  ≥7.0 by Agilent Bioanalyzer (Santa Clara, CA) were processed by the Mayo Clinic Medical Genome Facility Gene Expression Core into TruSeq libraries according to the manufacturer’s instructions (RNA Prep Kit v2, Illumina, San Diego, CA) and published elsewhere [25]. Paired-end DNA adaptors (Illumina) with a single “T” base overhang at the 3’end were immediately ligated to the “A-tailed” cDNA population. Unique indexes, included in the standard TruSeq Kits (12-Set A and 12-Set B), were incorporated at the adaptor ligation step for multiplex sample loading on the flow cells. Libraries (8–10 pM) were loaded onto paired-end flow cells to generate cluster densities of 700,000/mm2 following Illumina’s standard protocol for cBot and cBot paired-end cluster kit version 3. The flow cells were sequenced as 51 X 2 paired-end reads on an Illumina HiSeq 2000 using TruSeq SBS sequencing kit version 3 and HCS v2.0.12 data collection software. Base-calling was performed using RTA version 1.17.21.3."	"RNA integrity values of  ≥7.0 by Agilent Bioanalyzer (Santa Clara, CA) were processed by the Mayo Clinic Medical Genome Facility Gene Expression Core into TruSeq libraries according to the manufacturer’s instructions (RNA Prep Kit v2, Illumina, San Diego, CA) and published elsewhere [25]. Paired-end DNA adaptors (Illumina) with a single “T” base overhang at the 3’end were immediately ligated to the “A-tailed” cDNA population. Unique indexes, included in the standard TruSeq Kits (12-Set A and 12-Set B), were incorporated at the adaptor ligation step for multiplex sample loading on the flow cells. Libraries (8–10 pM) were loaded onto paired-end flow cells to generate cluster densities of 700,000/mm2 following Illumina’s standard protocol for cBot and cBot paired-end cluster kit version 3. The flow cells were sequenced as 51 X 2 paired-end reads on an Illumina HiSeq 2000 using TruSeq SBS sequencing kit version 3 and HCS v2.0.12 data collection software. Base-calling was performed using RTA version 1.17.21.3."	"RNA integrity values of  ≥7.0 by Agilent Bioanalyzer (Santa Clara, CA) were processed by the Mayo Clinic Medical Genome Facility Gene Expression Core into TruSeq libraries according to the manufacturer’s instructions (RNA Prep Kit v2, Illumina, San Diego, CA) and published elsewhere [25]. Paired-end DNA adaptors (Illumina) with a single “T” base overhang at the 3’end were immediately ligated to the “A-tailed” cDNA population. Unique indexes, included in the standard TruSeq Kits (12-Set A and 12-Set B), were incorporated at the adaptor ligation step for multiplex sample loading on the flow cells. Libraries (8–10 pM) were loaded onto paired-end flow cells to generate cluster densities of 700,000/mm2 following Illumina’s standard protocol for cBot and cBot paired-end cluster kit version 3. The flow cells were sequenced as 51 X 2 paired-end reads on an Illumina HiSeq 2000 using TruSeq SBS sequencing kit version 3 and HCS v2.0.12 data collection software. Base-calling was performed using RTA version 1.17.21.3."	"RNA integrity values of  ≥7.0 by Agilent Bioanalyzer (Santa Clara, CA) were processed by the Mayo Clinic Medical Genome Facility Gene Expression Core into TruSeq libraries according to the manufacturer’s instructions (RNA Prep Kit v2, Illumina, San Diego, CA) and published elsewhere [25]. Paired-end DNA adaptors (Illumina) with a single “T” base overhang at the 3’end were immediately ligated to the “A-tailed” cDNA population. Unique indexes, included in the standard TruSeq Kits (12-Set A and 12-Set B), were incorporated at the adaptor ligation step for multiplex sample loading on the flow cells. Libraries (8–10 pM) were loaded onto paired-end flow cells to generate cluster densities of 700,000/mm2 following Illumina’s standard protocol for cBot and cBot paired-end cluster kit version 3. The flow cells were sequenced as 51 X 2 paired-end reads on an Illumina HiSeq 2000 using TruSeq SBS sequencing kit version 3 and HCS v2.0.12 data collection software. Base-calling was performed using RTA version 1.17.21.3."	"RNA integrity values of  ≥7.0 by Agilent Bioanalyzer (Santa Clara, CA) were processed by the Mayo Clinic Medical Genome Facility Gene Expression Core into TruSeq libraries according to the manufacturer’s instructions (RNA Prep Kit v2, Illumina, San Diego, CA) and published elsewhere [25]. Paired-end DNA adaptors (Illumina) with a single “T” base overhang at the 3’end were immediately ligated to the “A-tailed” cDNA population. Unique indexes, included in the standard TruSeq Kits (12-Set A and 12-Set B), were incorporated at the adaptor ligation step for multiplex sample loading on the flow cells. Libraries (8–10 pM) were loaded onto paired-end flow cells to generate cluster densities of 700,000/mm2 following Illumina’s standard protocol for cBot and cBot paired-end cluster kit version 3. The flow cells were sequenced as 51 X 2 paired-end reads on an Illumina HiSeq 2000 using TruSeq SBS sequencing kit version 3 and HCS v2.0.12 data collection software. Base-calling was performed using RTA version 1.17.21.3."	"RNA integrity values of  ≥7.0 by Agilent Bioanalyzer (Santa Clara, CA) were processed by the Mayo Clinic Medical Genome Facility Gene Expression Core into TruSeq libraries according to the manufacturer’s instructions (RNA Prep Kit v2, Illumina, San Diego, CA) and published elsewhere [25]. Paired-end DNA adaptors (Illumina) with a single “T” base overhang at the 3’end were immediately ligated to the “A-tailed” cDNA population. Unique indexes, included in the standard TruSeq Kits (12-Set A and 12-Set B), were incorporated at the adaptor ligation step for multiplex sample loading on the flow cells. Libraries (8–10 pM) were loaded onto paired-end flow cells to generate cluster densities of 700,000/mm2 following Illumina’s standard protocol for cBot and cBot paired-end cluster kit version 3. The flow cells were sequenced as 51 X 2 paired-end reads on an Illumina HiSeq 2000 using TruSeq SBS sequencing kit version 3 and HCS v2.0.12 data collection software. Base-calling was performed using RTA version 1.17.21.3."	"RNA integrity values of  ≥7.0 by Agilent Bioanalyzer (Santa Clara, CA) were processed by the Mayo Clinic Medical Genome Facility Gene Expression Core into TruSeq libraries according to the manufacturer’s instructions (RNA Prep Kit v2, Illumina, San Diego, CA) and published elsewhere [25]. Paired-end DNA adaptors (Illumina) with a single “T” base overhang at the 3’end were immediately ligated to the “A-tailed” cDNA population. Unique indexes, included in the standard TruSeq Kits (12-Set A and 12-Set B), were incorporated at the adaptor ligation step for multiplex sample loading on the flow cells. Libraries (8–10 pM) were loaded onto paired-end flow cells to generate cluster densities of 700,000/mm2 following Illumina’s standard protocol for cBot and cBot paired-end cluster kit version 3. The flow cells were sequenced as 51 X 2 paired-end reads on an Illumina HiSeq 2000 using TruSeq SBS sequencing kit version 3 and HCS v2.0.12 data collection software. Base-calling was performed using RTA version 1.17.21.3."	"RNA integrity values of  ≥7.0 by Agilent Bioanalyzer (Santa Clara, CA) were processed by the Mayo Clinic Medical Genome Facility Gene Expression Core into TruSeq libraries according to the manufacturer’s instructions (RNA Prep Kit v2, Illumina, San Diego, CA) and published elsewhere [25]. Paired-end DNA adaptors (Illumina) with a single “T” base overhang at the 3’end were immediately ligated to the “A-tailed” cDNA population. Unique indexes, included in the standard TruSeq Kits (12-Set A and 12-Set B), were incorporated at the adaptor ligation step for multiplex sample loading on the flow cells. Libraries (8–10 pM) were loaded onto paired-end flow cells to generate cluster densities of 700,000/mm2 following Illumina’s standard protocol for cBot and cBot paired-end cluster kit version 3. The flow cells were sequenced as 51 X 2 paired-end reads on an Illumina HiSeq 2000 using TruSeq SBS sequencing kit version 3 and HCS v2.0.12 data collection software. Base-calling was performed using RTA version 1.17.21.3."	"RNA integrity values of  ≥7.0 by Agilent Bioanalyzer (Santa Clara, CA) were processed by the Mayo Clinic Medical Genome Facility Gene Expression Core into TruSeq libraries according to the manufacturer’s instructions (RNA Prep Kit v2, Illumina, San Diego, CA) and published elsewhere [25]. Paired-end DNA adaptors (Illumina) with a single “T” base overhang at the 3’end were immediately ligated to the “A-tailed” cDNA population. Unique indexes, included in the standard TruSeq Kits (12-Set A and 12-Set B), were incorporated at the adaptor ligation step for multiplex sample loading on the flow cells. Libraries (8–10 pM) were loaded onto paired-end flow cells to generate cluster densities of 700,000/mm2 following Illumina’s standard protocol for cBot and cBot paired-end cluster kit version 3. The flow cells were sequenced as 51 X 2 paired-end reads on an Illumina HiSeq 2000 using TruSeq SBS sequencing kit version 3 and HCS v2.0.12 data collection software. Base-calling was performed using RTA version 1.17.21.3."	"RNA integrity values of  ≥7.0 by Agilent Bioanalyzer (Santa Clara, CA) were processed by the Mayo Clinic Medical Genome Facility Gene Expression Core into TruSeq libraries according to the manufacturer’s instructions (RNA Prep Kit v2, Illumina, San Diego, CA) and published elsewhere [25]. Paired-end DNA adaptors (Illumina) with a single “T” base overhang at the 3’end were immediately ligated to the “A-tailed” cDNA population. Unique indexes, included in the standard TruSeq Kits (12-Set A and 12-Set B), were incorporated at the adaptor ligation step for multiplex sample loading on the flow cells. Libraries (8–10 pM) were loaded onto paired-end flow cells to generate cluster densities of 700,000/mm2 following Illumina’s standard protocol for cBot and cBot paired-end cluster kit version 3. The flow cells were sequenced as 51 X 2 paired-end reads on an Illumina HiSeq 2000 using TruSeq SBS sequencing kit version 3 and HCS v2.0.12 data collection software. Base-calling was performed using RTA version 1.17.21.3."	"RNA integrity values of  ≥7.0 by Agilent Bioanalyzer (Santa Clara, CA) were processed by the Mayo Clinic Medical Genome Facility Gene Expression Core into TruSeq libraries according to the manufacturer’s instructions (RNA Prep Kit v2, Illumina, San Diego, CA) and published elsewhere [25]. Paired-end DNA adaptors (Illumina) with a single “T” base overhang at the 3’end were immediately ligated to the “A-tailed” cDNA population. Unique indexes, included in the standard TruSeq Kits (12-Set A and 12-Set B), were incorporated at the adaptor ligation step for multiplex sample loading on the flow cells. Libraries (8–10 pM) were loaded onto paired-end flow cells to generate cluster densities of 700,000/mm2 following Illumina’s standard protocol for cBot and cBot paired-end cluster kit version 3. The flow cells were sequenced as 51 X 2 paired-end reads on an Illumina HiSeq 2000 using TruSeq SBS sequencing kit version 3 and HCS v2.0.12 data collection software. Base-calling was performed using RTA version 1.17.21.3."	"RNA integrity values of  ≥7.0 by Agilent Bioanalyzer (Santa Clara, CA) were processed by the Mayo Clinic Medical Genome Facility Gene Expression Core into TruSeq libraries according to the manufacturer’s instructions (RNA Prep Kit v2, Illumina, San Diego, CA) and published elsewhere [25]. Paired-end DNA adaptors (Illumina) with a single “T” base overhang at the 3’end were immediately ligated to the “A-tailed” cDNA population. Unique indexes, included in the standard TruSeq Kits (12-Set A and 12-Set B), were incorporated at the adaptor ligation step for multiplex sample loading on the flow cells. Libraries (8–10 pM) were loaded onto paired-end flow cells to generate cluster densities of 700,000/mm2 following Illumina’s standard protocol for cBot and cBot paired-end cluster kit version 3. The flow cells were sequenced as 51 X 2 paired-end reads on an Illumina HiSeq 2000 using TruSeq SBS sequencing kit version 3 and HCS v2.0.12 data collection software. Base-calling was performed using RTA version 1.17.21.3."	"RNA integrity values of  ≥7.0 by Agilent Bioanalyzer (Santa Clara, CA) were processed by the Mayo Clinic Medical Genome Facility Gene Expression Core into TruSeq libraries according to the manufacturer’s instructions (RNA Prep Kit v2, Illumina, San Diego, CA) and published elsewhere [25]. Paired-end DNA adaptors (Illumina) with a single “T” base overhang at the 3’end were immediately ligated to the “A-tailed” cDNA population. Unique indexes, included in the standard TruSeq Kits (12-Set A and 12-Set B), were incorporated at the adaptor ligation step for multiplex sample loading on the flow cells. Libraries (8–10 pM) were loaded onto paired-end flow cells to generate cluster densities of 700,000/mm2 following Illumina’s standard protocol for cBot and cBot paired-end cluster kit version 3. The flow cells were sequenced as 51 X 2 paired-end reads on an Illumina HiSeq 2000 using TruSeq SBS sequencing kit version 3 and HCS v2.0.12 data collection software. Base-calling was performed using RTA version 1.17.21.3."	"RNA integrity values of  ≥7.0 by Agilent Bioanalyzer (Santa Clara, CA) were processed by the Mayo Clinic Medical Genome Facility Gene Expression Core into TruSeq libraries according to the manufacturer’s instructions (RNA Prep Kit v2, Illumina, San Diego, CA) and published elsewhere [25]. Paired-end DNA adaptors (Illumina) with a single “T” base overhang at the 3’end were immediately ligated to the “A-tailed” cDNA population. Unique indexes, included in the standard TruSeq Kits (12-Set A and 12-Set B), were incorporated at the adaptor ligation step for multiplex sample loading on the flow cells. Libraries (8–10 pM) were loaded onto paired-end flow cells to generate cluster densities of 700,000/mm2 following Illumina’s standard protocol for cBot and cBot paired-end cluster kit version 3. The flow cells were sequenced as 51 X 2 paired-end reads on an Illumina HiSeq 2000 using TruSeq SBS sequencing kit version 3 and HCS v2.0.12 data collection software. Base-calling was performed using RTA version 1.17.21.3."	"RNA integrity values of  ≥7.0 by Agilent Bioanalyzer (Santa Clara, CA) were processed by the Mayo Clinic Medical Genome Facility Gene Expression Core into TruSeq libraries according to the manufacturer’s instructions (RNA Prep Kit v2, Illumina, San Diego, CA) and published elsewhere [25]. Paired-end DNA adaptors (Illumina) with a single “T” base overhang at the 3’end were immediately ligated to the “A-tailed” cDNA population. Unique indexes, included in the standard TruSeq Kits (12-Set A and 12-Set B), were incorporated at the adaptor ligation step for multiplex sample loading on the flow cells. Libraries (8–10 pM) were loaded onto paired-end flow cells to generate cluster densities of 700,000/mm2 following Illumina’s standard protocol for cBot and cBot paired-end cluster kit version 3. The flow cells were sequenced as 51 X 2 paired-end reads on an Illumina HiSeq 2000 using TruSeq SBS sequencing kit version 3 and HCS v2.0.12 data collection software. Base-calling was performed using RTA version 1.17.21.3."	"RNA integrity values of  ≥7.0 by Agilent Bioanalyzer (Santa Clara, CA) were processed by the Mayo Clinic Medical Genome Facility Gene Expression Core into TruSeq libraries according to the manufacturer’s instructions (RNA Prep Kit v2, Illumina, San Diego, CA) and published elsewhere [25]. Paired-end DNA adaptors (Illumina) with a single “T” base overhang at the 3’end were immediately ligated to the “A-tailed” cDNA population. Unique indexes, included in the standard TruSeq Kits (12-Set A and 12-Set B), were incorporated at the adaptor ligation step for multiplex sample loading on the flow cells. Libraries (8–10 pM) were loaded onto paired-end flow cells to generate cluster densities of 700,000/mm2 following Illumina’s standard protocol for cBot and cBot paired-end cluster kit version 3. The flow cells were sequenced as 51 X 2 paired-end reads on an Illumina HiSeq 2000 using TruSeq SBS sequencing kit version 3 and HCS v2.0.12 data collection software. Base-calling was performed using RTA version 1.17.21.3."	"RNA integrity values of  ≥7.0 by Agilent Bioanalyzer (Santa Clara, CA) were processed by the Mayo Clinic Medical Genome Facility Gene Expression Core into TruSeq libraries according to the manufacturer’s instructions (RNA Prep Kit v2, Illumina, San Diego, CA) and published elsewhere [25]. Paired-end DNA adaptors (Illumina) with a single “T” base overhang at the 3’end were immediately ligated to the “A-tailed” cDNA population. Unique indexes, included in the standard TruSeq Kits (12-Set A and 12-Set B), were incorporated at the adaptor ligation step for multiplex sample loading on the flow cells. Libraries (8–10 pM) were loaded onto paired-end flow cells to generate cluster densities of 700,000/mm2 following Illumina’s standard protocol for cBot and cBot paired-end cluster kit version 3. The flow cells were sequenced as 51 X 2 paired-end reads on an Illumina HiSeq 2000 using TruSeq SBS sequencing kit version 3 and HCS v2.0.12 data collection software. Base-calling was performed using RTA version 1.17.21.3."	"RNA integrity values of  ≥7.0 by Agilent Bioanalyzer (Santa Clara, CA) were processed by the Mayo Clinic Medical Genome Facility Gene Expression Core into TruSeq libraries according to the manufacturer’s instructions (RNA Prep Kit v2, Illumina, San Diego, CA) and published elsewhere [25]. Paired-end DNA adaptors (Illumina) with a single “T” base overhang at the 3’end were immediately ligated to the “A-tailed” cDNA population. Unique indexes, included in the standard TruSeq Kits (12-Set A and 12-Set B), were incorporated at the adaptor ligation step for multiplex sample loading on the flow cells. Libraries (8–10 pM) were loaded onto paired-end flow cells to generate cluster densities of 700,000/mm2 following Illumina’s standard protocol for cBot and cBot paired-end cluster kit version 3. The flow cells were sequenced as 51 X 2 paired-end reads on an Illumina HiSeq 2000 using TruSeq SBS sequencing kit version 3 and HCS v2.0.12 data collection software. Base-calling was performed using RTA version 1.17.21.3."	"RNA integrity values of  ≥7.0 by Agilent Bioanalyzer (Santa Clara, CA) were processed by the Mayo Clinic Medical Genome Facility Gene Expression Core into TruSeq libraries according to the manufacturer’s instructions (RNA Prep Kit v2, Illumina, San Diego, CA) and published elsewhere [25]. Paired-end DNA adaptors (Illumina) with a single “T” base overhang at the 3’end were immediately ligated to the “A-tailed” cDNA population. Unique indexes, included in the standard TruSeq Kits (12-Set A and 12-Set B), were incorporated at the adaptor ligation step for multiplex sample loading on the flow cells. Libraries (8–10 pM) were loaded onto paired-end flow cells to generate cluster densities of 700,000/mm2 following Illumina’s standard protocol for cBot and cBot paired-end cluster kit version 3. The flow cells were sequenced as 51 X 2 paired-end reads on an Illumina HiSeq 2000 using TruSeq SBS sequencing kit version 3 and HCS v2.0.12 data collection software. Base-calling was performed using RTA version 1.17.21.3."
!Sample_data_processing	"All biological samples were sequenced using Illumina HiSeq™ 2000 platform (Illumina) with 50-bp pair-end sequencing protocol in the Mayo DNA Sequencing Core Facility. Raw RNA-seq reads from each RNA-seq library were assessed for duplication rate and gene coverage using FastQC."	"All biological samples were sequenced using Illumina HiSeq™ 2000 platform (Illumina) with 50-bp pair-end sequencing protocol in the Mayo DNA Sequencing Core Facility. Raw RNA-seq reads from each RNA-seq library were assessed for duplication rate and gene coverage using FastQC."	"All biological samples were sequenced using Illumina HiSeq™ 2000 platform (Illumina) with 50-bp pair-end sequencing protocol in the Mayo DNA Sequencing Core Facility. Raw RNA-seq reads from each RNA-seq library were assessed for duplication rate and gene coverage using FastQC."	"All biological samples were sequenced using Illumina HiSeq™ 2000 platform (Illumina) with 50-bp pair-end sequencing protocol in the Mayo DNA Sequencing Core Facility. Raw RNA-seq reads from each RNA-seq library were assessed for duplication rate and gene coverage using FastQC."	"All biological samples were sequenced using Illumina HiSeq™ 2000 platform (Illumina) with 50-bp pair-end sequencing protocol in the Mayo DNA Sequencing Core Facility. Raw RNA-seq reads from each RNA-seq library were assessed for duplication rate and gene coverage using FastQC."	"All biological samples were sequenced using Illumina HiSeq™ 2000 platform (Illumina) with 50-bp pair-end sequencing protocol in the Mayo DNA Sequencing Core Facility. Raw RNA-seq reads from each RNA-seq library were assessed for duplication rate and gene coverage using FastQC."	"All biological samples were sequenced using Illumina HiSeq™ 2000 platform (Illumina) with 50-bp pair-end sequencing protocol in the Mayo DNA Sequencing Core Facility. Raw RNA-seq reads from each RNA-seq library were assessed for duplication rate and gene coverage using FastQC."	"All biological samples were sequenced using Illumina HiSeq™ 2000 platform (Illumina) with 50-bp pair-end sequencing protocol in the Mayo DNA Sequencing Core Facility. Raw RNA-seq reads from each RNA-seq library were assessed for duplication rate and gene coverage using FastQC."	"All biological samples were sequenced using Illumina HiSeq™ 2000 platform (Illumina) with 50-bp pair-end sequencing protocol in the Mayo DNA Sequencing Core Facility. Raw RNA-seq reads from each RNA-seq library were assessed for duplication rate and gene coverage using FastQC."	"All biological samples were sequenced using Illumina HiSeq™ 2000 platform (Illumina) with 50-bp pair-end sequencing protocol in the Mayo DNA Sequencing Core Facility. Raw RNA-seq reads from each RNA-seq library were assessed for duplication rate and gene coverage using FastQC."	"All biological samples were sequenced using Illumina HiSeq™ 2000 platform (Illumina) with 50-bp pair-end sequencing protocol in the Mayo DNA Sequencing Core Facility. Raw RNA-seq reads from each RNA-seq library were assessed for duplication rate and gene coverage using FastQC."	"All biological samples were sequenced using Illumina HiSeq™ 2000 platform (Illumina) with 50-bp pair-end sequencing protocol in the Mayo DNA Sequencing Core Facility. Raw RNA-seq reads from each RNA-seq library were assessed for duplication rate and gene coverage using FastQC."	"All biological samples were sequenced using Illumina HiSeq™ 2000 platform (Illumina) with 50-bp pair-end sequencing protocol in the Mayo DNA Sequencing Core Facility. Raw RNA-seq reads from each RNA-seq library were assessed for duplication rate and gene coverage using FastQC."	"All biological samples were sequenced using Illumina HiSeq™ 2000 platform (Illumina) with 50-bp pair-end sequencing protocol in the Mayo DNA Sequencing Core Facility. Raw RNA-seq reads from each RNA-seq library were assessed for duplication rate and gene coverage using FastQC."	"All biological samples were sequenced using Illumina HiSeq™ 2000 platform (Illumina) with 50-bp pair-end sequencing protocol in the Mayo DNA Sequencing Core Facility. Raw RNA-seq reads from each RNA-seq library were assessed for duplication rate and gene coverage using FastQC."	"All biological samples were sequenced using Illumina HiSeq™ 2000 platform (Illumina) with 50-bp pair-end sequencing protocol in the Mayo DNA Sequencing Core Facility. Raw RNA-seq reads from each RNA-seq library were assessed for duplication rate and gene coverage using FastQC."	"All biological samples were sequenced using Illumina HiSeq™ 2000 platform (Illumina) with 50-bp pair-end sequencing protocol in the Mayo DNA Sequencing Core Facility. Raw RNA-seq reads from each RNA-seq library were assessed for duplication rate and gene coverage using FastQC."	"All biological samples were sequenced using Illumina HiSeq™ 2000 platform (Illumina) with 50-bp pair-end sequencing protocol in the Mayo DNA Sequencing Core Facility. Raw RNA-seq reads from each RNA-seq library were assessed for duplication rate and gene coverage using FastQC."	"All biological samples were sequenced using Illumina HiSeq™ 2000 platform (Illumina) with 50-bp pair-end sequencing protocol in the Mayo DNA Sequencing Core Facility. Raw RNA-seq reads from each RNA-seq library were assessed for duplication rate and gene coverage using FastQC."	"All biological samples were sequenced using Illumina HiSeq™ 2000 platform (Illumina) with 50-bp pair-end sequencing protocol in the Mayo DNA Sequencing Core Facility. Raw RNA-seq reads from each RNA-seq library were assessed for duplication rate and gene coverage using FastQC."	"All biological samples were sequenced using Illumina HiSeq™ 2000 platform (Illumina) with 50-bp pair-end sequencing protocol in the Mayo DNA Sequencing Core Facility. Raw RNA-seq reads from each RNA-seq library were assessed for duplication rate and gene coverage using FastQC."	"All biological samples were sequenced using Illumina HiSeq™ 2000 platform (Illumina) with 50-bp pair-end sequencing protocol in the Mayo DNA Sequencing Core Facility. Raw RNA-seq reads from each RNA-seq library were assessed for duplication rate and gene coverage using FastQC."	"All biological samples were sequenced using Illumina HiSeq™ 2000 platform (Illumina) with 50-bp pair-end sequencing protocol in the Mayo DNA Sequencing Core Facility. Raw RNA-seq reads from each RNA-seq library were assessed for duplication rate and gene coverage using FastQC."	"All biological samples were sequenced using Illumina HiSeq™ 2000 platform (Illumina) with 50-bp pair-end sequencing protocol in the Mayo DNA Sequencing Core Facility. Raw RNA-seq reads from each RNA-seq library were assessed for duplication rate and gene coverage using FastQC."	"All biological samples were sequenced using Illumina HiSeq™ 2000 platform (Illumina) with 50-bp pair-end sequencing protocol in the Mayo DNA Sequencing Core Facility. Raw RNA-seq reads from each RNA-seq library were assessed for duplication rate and gene coverage using FastQC."	"All biological samples were sequenced using Illumina HiSeq™ 2000 platform (Illumina) with 50-bp pair-end sequencing protocol in the Mayo DNA Sequencing Core Facility. Raw RNA-seq reads from each RNA-seq library were assessed for duplication rate and gene coverage using FastQC."	"All biological samples were sequenced using Illumina HiSeq™ 2000 platform (Illumina) with 50-bp pair-end sequencing protocol in the Mayo DNA Sequencing Core Facility. Raw RNA-seq reads from each RNA-seq library were assessed for duplication rate and gene coverage using FastQC."	"All biological samples were sequenced using Illumina HiSeq™ 2000 platform (Illumina) with 50-bp pair-end sequencing protocol in the Mayo DNA Sequencing Core Facility. Raw RNA-seq reads from each RNA-seq library were assessed for duplication rate and gene coverage using FastQC."	"All biological samples were sequenced using Illumina HiSeq™ 2000 platform (Illumina) with 50-bp pair-end sequencing protocol in the Mayo DNA Sequencing Core Facility. Raw RNA-seq reads from each RNA-seq library were assessed for duplication rate and gene coverage using FastQC."
!Sample_data_processing	"Raw RNA-seq reads were aligned to the human genome assembly (GRCh38) for per sample using the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf) by the HISAT2 (Version 2.0.4)"	"Raw RNA-seq reads were aligned to the human genome assembly (GRCh38) for per sample using the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf) by the HISAT2 (Version 2.0.4)"	"Raw RNA-seq reads were aligned to the human genome assembly (GRCh38) for per sample using the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf) by the HISAT2 (Version 2.0.4)"	"Raw RNA-seq reads were aligned to the human genome assembly (GRCh38) for per sample using the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf) by the HISAT2 (Version 2.0.4)"	"Raw RNA-seq reads were aligned to the human genome assembly (GRCh38) for per sample using the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf) by the HISAT2 (Version 2.0.4)"	"Raw RNA-seq reads were aligned to the human genome assembly (GRCh38) for per sample using the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf) by the HISAT2 (Version 2.0.4)"	"Raw RNA-seq reads were aligned to the human genome assembly (GRCh38) for per sample using the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf) by the HISAT2 (Version 2.0.4)"	"Raw RNA-seq reads were aligned to the human genome assembly (GRCh38) for per sample using the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf) by the HISAT2 (Version 2.0.4)"	"Raw RNA-seq reads were aligned to the human genome assembly (GRCh38) for per sample using the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf) by the HISAT2 (Version 2.0.4)"	"Raw RNA-seq reads were aligned to the human genome assembly (GRCh38) for per sample using the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf) by the HISAT2 (Version 2.0.4)"	"Raw RNA-seq reads were aligned to the human genome assembly (GRCh38) for per sample using the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf) by the HISAT2 (Version 2.0.4)"	"Raw RNA-seq reads were aligned to the human genome assembly (GRCh38) for per sample using the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf) by the HISAT2 (Version 2.0.4)"	"Raw RNA-seq reads were aligned to the human genome assembly (GRCh38) for per sample using the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf) by the HISAT2 (Version 2.0.4)"	"Raw RNA-seq reads were aligned to the human genome assembly (GRCh38) for per sample using the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf) by the HISAT2 (Version 2.0.4)"	"Raw RNA-seq reads were aligned to the human genome assembly (GRCh38) for per sample using the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf) by the HISAT2 (Version 2.0.4)"	"Raw RNA-seq reads were aligned to the human genome assembly (GRCh38) for per sample using the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf) by the HISAT2 (Version 2.0.4)"	"Raw RNA-seq reads were aligned to the human genome assembly (GRCh38) for per sample using the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf) by the HISAT2 (Version 2.0.4)"	"Raw RNA-seq reads were aligned to the human genome assembly (GRCh38) for per sample using the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf) by the HISAT2 (Version 2.0.4)"	"Raw RNA-seq reads were aligned to the human genome assembly (GRCh38) for per sample using the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf) by the HISAT2 (Version 2.0.4)"	"Raw RNA-seq reads were aligned to the human genome assembly (GRCh38) for per sample using the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf) by the HISAT2 (Version 2.0.4)"	"Raw RNA-seq reads were aligned to the human genome assembly (GRCh38) for per sample using the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf) by the HISAT2 (Version 2.0.4)"	"Raw RNA-seq reads were aligned to the human genome assembly (GRCh38) for per sample using the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf) by the HISAT2 (Version 2.0.4)"	"Raw RNA-seq reads were aligned to the human genome assembly (GRCh38) for per sample using the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf) by the HISAT2 (Version 2.0.4)"	"Raw RNA-seq reads were aligned to the human genome assembly (GRCh38) for per sample using the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf) by the HISAT2 (Version 2.0.4)"	"Raw RNA-seq reads were aligned to the human genome assembly (GRCh38) for per sample using the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf) by the HISAT2 (Version 2.0.4)"	"Raw RNA-seq reads were aligned to the human genome assembly (GRCh38) for per sample using the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf) by the HISAT2 (Version 2.0.4)"	"Raw RNA-seq reads were aligned to the human genome assembly (GRCh38) for per sample using the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf) by the HISAT2 (Version 2.0.4)"	"Raw RNA-seq reads were aligned to the human genome assembly (GRCh38) for per sample using the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf) by the HISAT2 (Version 2.0.4)"	"Raw RNA-seq reads were aligned to the human genome assembly (GRCh38) for per sample using the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf) by the HISAT2 (Version 2.0.4)"
!Sample_data_processing	"The quality control of RNA-seq was conducted and gene counts were computed by the Qualimap (Version 2.2) with the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf). The results of the quality control based on the Qualimap were assembled using the MultiQC"	"The quality control of RNA-seq was conducted and gene counts were computed by the Qualimap (Version 2.2) with the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf). The results of the quality control based on the Qualimap were assembled using the MultiQC"	"The quality control of RNA-seq was conducted and gene counts were computed by the Qualimap (Version 2.2) with the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf). The results of the quality control based on the Qualimap were assembled using the MultiQC"	"The quality control of RNA-seq was conducted and gene counts were computed by the Qualimap (Version 2.2) with the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf). The results of the quality control based on the Qualimap were assembled using the MultiQC"	"The quality control of RNA-seq was conducted and gene counts were computed by the Qualimap (Version 2.2) with the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf). The results of the quality control based on the Qualimap were assembled using the MultiQC"	"The quality control of RNA-seq was conducted and gene counts were computed by the Qualimap (Version 2.2) with the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf). The results of the quality control based on the Qualimap were assembled using the MultiQC"	"The quality control of RNA-seq was conducted and gene counts were computed by the Qualimap (Version 2.2) with the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf). The results of the quality control based on the Qualimap were assembled using the MultiQC"	"The quality control of RNA-seq was conducted and gene counts were computed by the Qualimap (Version 2.2) with the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf). The results of the quality control based on the Qualimap were assembled using the MultiQC"	"The quality control of RNA-seq was conducted and gene counts were computed by the Qualimap (Version 2.2) with the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf). The results of the quality control based on the Qualimap were assembled using the MultiQC"	"The quality control of RNA-seq was conducted and gene counts were computed by the Qualimap (Version 2.2) with the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf). The results of the quality control based on the Qualimap were assembled using the MultiQC"	"The quality control of RNA-seq was conducted and gene counts were computed by the Qualimap (Version 2.2) with the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf). The results of the quality control based on the Qualimap were assembled using the MultiQC"	"The quality control of RNA-seq was conducted and gene counts were computed by the Qualimap (Version 2.2) with the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf). The results of the quality control based on the Qualimap were assembled using the MultiQC"	"The quality control of RNA-seq was conducted and gene counts were computed by the Qualimap (Version 2.2) with the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf). The results of the quality control based on the Qualimap were assembled using the MultiQC"	"The quality control of RNA-seq was conducted and gene counts were computed by the Qualimap (Version 2.2) with the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf). The results of the quality control based on the Qualimap were assembled using the MultiQC"	"The quality control of RNA-seq was conducted and gene counts were computed by the Qualimap (Version 2.2) with the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf). The results of the quality control based on the Qualimap were assembled using the MultiQC"	"The quality control of RNA-seq was conducted and gene counts were computed by the Qualimap (Version 2.2) with the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf). The results of the quality control based on the Qualimap were assembled using the MultiQC"	"The quality control of RNA-seq was conducted and gene counts were computed by the Qualimap (Version 2.2) with the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf). The results of the quality control based on the Qualimap were assembled using the MultiQC"	"The quality control of RNA-seq was conducted and gene counts were computed by the Qualimap (Version 2.2) with the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf). The results of the quality control based on the Qualimap were assembled using the MultiQC"	"The quality control of RNA-seq was conducted and gene counts were computed by the Qualimap (Version 2.2) with the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf). The results of the quality control based on the Qualimap were assembled using the MultiQC"	"The quality control of RNA-seq was conducted and gene counts were computed by the Qualimap (Version 2.2) with the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf). The results of the quality control based on the Qualimap were assembled using the MultiQC"	"The quality control of RNA-seq was conducted and gene counts were computed by the Qualimap (Version 2.2) with the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf). The results of the quality control based on the Qualimap were assembled using the MultiQC"	"The quality control of RNA-seq was conducted and gene counts were computed by the Qualimap (Version 2.2) with the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf). The results of the quality control based on the Qualimap were assembled using the MultiQC"	"The quality control of RNA-seq was conducted and gene counts were computed by the Qualimap (Version 2.2) with the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf). The results of the quality control based on the Qualimap were assembled using the MultiQC"	"The quality control of RNA-seq was conducted and gene counts were computed by the Qualimap (Version 2.2) with the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf). The results of the quality control based on the Qualimap were assembled using the MultiQC"	"The quality control of RNA-seq was conducted and gene counts were computed by the Qualimap (Version 2.2) with the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf). The results of the quality control based on the Qualimap were assembled using the MultiQC"	"The quality control of RNA-seq was conducted and gene counts were computed by the Qualimap (Version 2.2) with the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf). The results of the quality control based on the Qualimap were assembled using the MultiQC"	"The quality control of RNA-seq was conducted and gene counts were computed by the Qualimap (Version 2.2) with the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf). The results of the quality control based on the Qualimap were assembled using the MultiQC"	"The quality control of RNA-seq was conducted and gene counts were computed by the Qualimap (Version 2.2) with the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf). The results of the quality control based on the Qualimap were assembled using the MultiQC"	"The quality control of RNA-seq was conducted and gene counts were computed by the Qualimap (Version 2.2) with the Ensembl annotation (Homo_sapiens.GRCh38.84.gtf). The results of the quality control based on the Qualimap were assembled using the MultiQC"
!Sample_data_processing	"Genome_build: GRCh38"	"Genome_build: GRCh38"	"Genome_build: GRCh38"	"Genome_build: GRCh38"	"Genome_build: GRCh38"	"Genome_build: GRCh38"	"Genome_build: GRCh38"	"Genome_build: GRCh38"	"Genome_build: GRCh38"	"Genome_build: GRCh38"	"Genome_build: GRCh38"	"Genome_build: GRCh38"	"Genome_build: GRCh38"	"Genome_build: GRCh38"	"Genome_build: GRCh38"	"Genome_build: GRCh38"	"Genome_build: GRCh38"	"Genome_build: GRCh38"	"Genome_build: GRCh38"	"Genome_build: GRCh38"	"Genome_build: GRCh38"	"Genome_build: GRCh38"	"Genome_build: GRCh38"	"Genome_build: GRCh38"	"Genome_build: GRCh38"	"Genome_build: GRCh38"	"Genome_build: GRCh38"	"Genome_build: GRCh38"	"Genome_build: GRCh38"
!Sample_data_processing	"Supplementary_files_format_and_content: Tab-delimited text files of gene count values for each Sample"	"Supplementary_files_format_and_content: Tab-delimited text files of gene count values for each Sample"	"Supplementary_files_format_and_content: Tab-delimited text files of gene count values for each Sample"	"Supplementary_files_format_and_content: Tab-delimited text files of gene count values for each Sample"	"Supplementary_files_format_and_content: Tab-delimited text files of gene count values for each Sample"	"Supplementary_files_format_and_content: Tab-delimited text files of gene count values for each Sample"	"Supplementary_files_format_and_content: Tab-delimited text files of gene count values for each Sample"	"Supplementary_files_format_and_content: Tab-delimited text files of gene count values for each Sample"	"Supplementary_files_format_and_content: Tab-delimited text files of gene count values for each Sample"	"Supplementary_files_format_and_content: Tab-delimited text files of gene count values for each Sample"	"Supplementary_files_format_and_content: Tab-delimited text files of gene count values for each Sample"	"Supplementary_files_format_and_content: Tab-delimited text files of gene count values for each Sample"	"Supplementary_files_format_and_content: Tab-delimited text files of gene count values for each Sample"	"Supplementary_files_format_and_content: Tab-delimited text files of gene count values for each Sample"	"Supplementary_files_format_and_content: Tab-delimited text files of gene count values for each Sample"	"Supplementary_files_format_and_content: Tab-delimited text files of gene count values for each Sample"	"Supplementary_files_format_and_content: Tab-delimited text files of gene count values for each Sample"	"Supplementary_files_format_and_content: Tab-delimited text files of gene count values for each Sample"	"Supplementary_files_format_and_content: Tab-delimited text files of gene count values for each Sample"	"Supplementary_files_format_and_content: Tab-delimited text files of gene count values for each Sample"	"Supplementary_files_format_and_content: Tab-delimited text files of gene count values for each Sample"	"Supplementary_files_format_and_content: Tab-delimited text files of gene count values for each Sample"	"Supplementary_files_format_and_content: Tab-delimited text files of gene count values for each Sample"	"Supplementary_files_format_and_content: Tab-delimited text files of gene count values for each Sample"	"Supplementary_files_format_and_content: Tab-delimited text files of gene count values for each Sample"	"Supplementary_files_format_and_content: Tab-delimited text files of gene count values for each Sample"	"Supplementary_files_format_and_content: Tab-delimited text files of gene count values for each Sample"	"Supplementary_files_format_and_content: Tab-delimited text files of gene count values for each Sample"	"Supplementary_files_format_and_content: Tab-delimited text files of gene count values for each Sample"
!Sample_platform_id	"GPL11154"	"GPL11154"	"GPL11154"	"GPL11154"	"GPL11154"	"GPL11154"	"GPL11154"	"GPL11154"	"GPL11154"	"GPL11154"	"GPL11154"	"GPL11154"	"GPL11154"	"GPL11154"	"GPL11154"	"GPL11154"	"GPL11154"	"GPL11154"	"GPL11154"	"GPL11154"	"GPL11154"	"GPL11154"	"GPL11154"	"GPL11154"	"GPL11154"	"GPL11154"	"GPL11154"	"GPL11154"	"GPL11154"
!Sample_contact_name	"Yuji,,Zhang"	"Yuji,,Zhang"	"Yuji,,Zhang"	"Yuji,,Zhang"	"Yuji,,Zhang"	"Yuji,,Zhang"	"Yuji,,Zhang"	"Yuji,,Zhang"	"Yuji,,Zhang"	"Yuji,,Zhang"	"Yuji,,Zhang"	"Yuji,,Zhang"	"Yuji,,Zhang"	"Yuji,,Zhang"	"Yuji,,Zhang"	"Yuji,,Zhang"	"Yuji,,Zhang"	"Yuji,,Zhang"	"Yuji,,Zhang"	"Yuji,,Zhang"	"Yuji,,Zhang"	"Yuji,,Zhang"	"Yuji,,Zhang"	"Yuji,,Zhang"	"Yuji,,Zhang"	"Yuji,,Zhang"	"Yuji,,Zhang"	"Yuji,,Zhang"	"Yuji,,Zhang"
!Sample_contact_email	"yuzhang@som.umaryland.edu"	"yuzhang@som.umaryland.edu"	"yuzhang@som.umaryland.edu"	"yuzhang@som.umaryland.edu"	"yuzhang@som.umaryland.edu"	"yuzhang@som.umaryland.edu"	"yuzhang@som.umaryland.edu"	"yuzhang@som.umaryland.edu"	"yuzhang@som.umaryland.edu"	"yuzhang@som.umaryland.edu"	"yuzhang@som.umaryland.edu"	"yuzhang@som.umaryland.edu"	"yuzhang@som.umaryland.edu"	"yuzhang@som.umaryland.edu"	"yuzhang@som.umaryland.edu"	"yuzhang@som.umaryland.edu"	"yuzhang@som.umaryland.edu"	"yuzhang@som.umaryland.edu"	"yuzhang@som.umaryland.edu"	"yuzhang@som.umaryland.edu"	"yuzhang@som.umaryland.edu"	"yuzhang@som.umaryland.edu"	"yuzhang@som.umaryland.edu"	"yuzhang@som.umaryland.edu"	"yuzhang@som.umaryland.edu"	"yuzhang@som.umaryland.edu"	"yuzhang@som.umaryland.edu"	"yuzhang@som.umaryland.edu"	"yuzhang@som.umaryland.edu"
!Sample_contact_phone	"410-706-8523"	"410-706-8523"	"410-706-8523"	"410-706-8523"	"410-706-8523"	"410-706-8523"	"410-706-8523"	"410-706-8523"	"410-706-8523"	"410-706-8523"	"410-706-8523"	"410-706-8523"	"410-706-8523"	"410-706-8523"	"410-706-8523"	"410-706-8523"	"410-706-8523"	"410-706-8523"	"410-706-8523"	"410-706-8523"	"410-706-8523"	"410-706-8523"	"410-706-8523"	"410-706-8523"	"410-706-8523"	"410-706-8523"	"410-706-8523"	"410-706-8523"	"410-706-8523"
!Sample_contact_institute	"University of Maryland"	"University of Maryland"	"University of Maryland"	"University of Maryland"	"University of Maryland"	"University of Maryland"	"University of Maryland"	"University of Maryland"	"University of Maryland"	"University of Maryland"	"University of Maryland"	"University of Maryland"	"University of Maryland"	"University of Maryland"	"University of Maryland"	"University of Maryland"	"University of Maryland"	"University of Maryland"	"University of Maryland"	"University of Maryland"	"University of Maryland"	"University of Maryland"	"University of Maryland"	"University of Maryland"	"University of Maryland"	"University of Maryland"	"University of Maryland"	"University of Maryland"	"University of Maryland"
!Sample_contact_address	"660 W. Redwood Street"	"660 W. Redwood Street"	"660 W. Redwood Street"	"660 W. Redwood Street"	"660 W. Redwood Street"	"660 W. Redwood Street"	"660 W. Redwood Street"	"660 W. Redwood Street"	"660 W. Redwood Street"	"660 W. Redwood Street"	"660 W. Redwood Street"	"660 W. Redwood Street"	"660 W. Redwood Street"	"660 W. Redwood Street"	"660 W. Redwood Street"	"660 W. Redwood Street"	"660 W. Redwood Street"	"660 W. Redwood Street"	"660 W. Redwood Street"	"660 W. Redwood Street"	"660 W. Redwood Street"	"660 W. Redwood Street"	"660 W. Redwood Street"	"660 W. Redwood Street"	"660 W. Redwood Street"	"660 W. Redwood Street"	"660 W. Redwood Street"	"660 W. Redwood Street"	"660 W. Redwood Street"
!Sample_contact_city	"Baltimore"	"Baltimore"	"Baltimore"	"Baltimore"	"Baltimore"	"Baltimore"	"Baltimore"	"Baltimore"	"Baltimore"	"Baltimore"	"Baltimore"	"Baltimore"	"Baltimore"	"Baltimore"	"Baltimore"	"Baltimore"	"Baltimore"	"Baltimore"	"Baltimore"	"Baltimore"	"Baltimore"	"Baltimore"	"Baltimore"	"Baltimore"	"Baltimore"	"Baltimore"	"Baltimore"	"Baltimore"	"Baltimore"
!Sample_contact_state	"MD"	"MD"	"MD"	"MD"	"MD"	"MD"	"MD"	"MD"	"MD"	"MD"	"MD"	"MD"	"MD"	"MD"	"MD"	"MD"	"MD"	"MD"	"MD"	"MD"	"MD"	"MD"	"MD"	"MD"	"MD"	"MD"	"MD"	"MD"	"MD"
!Sample_contact_zip/postal_code	"21201"	"21201"	"21201"	"21201"	"21201"	"21201"	"21201"	"21201"	"21201"	"21201"	"21201"	"21201"	"21201"	"21201"	"21201"	"21201"	"21201"	"21201"	"21201"	"21201"	"21201"	"21201"	"21201"	"21201"	"21201"	"21201"	"21201"	"21201"	"21201"
!Sample_contact_country	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"
!Sample_data_row_count	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"
!Sample_instrument_model	"Illumina HiSeq 2000"	"Illumina HiSeq 2000"	"Illumina HiSeq 2000"	"Illumina HiSeq 2000"	"Illumina HiSeq 2000"	"Illumina HiSeq 2000"	"Illumina HiSeq 2000"	"Illumina HiSeq 2000"	"Illumina HiSeq 2000"	"Illumina HiSeq 2000"	"Illumina HiSeq 2000"	"Illumina HiSeq 2000"	"Illumina HiSeq 2000"	"Illumina HiSeq 2000"	"Illumina HiSeq 2000"	"Illumina HiSeq 2000"	"Illumina HiSeq 2000"	"Illumina HiSeq 2000"	"Illumina HiSeq 2000"	"Illumina HiSeq 2000"	"Illumina HiSeq 2000"	"Illumina HiSeq 2000"	"Illumina HiSeq 2000"	"Illumina HiSeq 2000"	"Illumina HiSeq 2000"	"Illumina HiSeq 2000"	"Illumina HiSeq 2000"	"Illumina HiSeq 2000"	"Illumina HiSeq 2000"
!Sample_library_selection	"cDNA"	"cDNA"	"cDNA"	"cDNA"	"cDNA"	"cDNA"	"cDNA"	"cDNA"	"cDNA"	"cDNA"	"cDNA"	"cDNA"	"cDNA"	"cDNA"	"cDNA"	"cDNA"	"cDNA"	"cDNA"	"cDNA"	"cDNA"	"cDNA"	"cDNA"	"cDNA"	"cDNA"	"cDNA"	"cDNA"	"cDNA"	"cDNA"	"cDNA"
!Sample_library_source	"transcriptomic"	"transcriptomic"	"transcriptomic"	"transcriptomic"	"transcriptomic"	"transcriptomic"	"transcriptomic"	"transcriptomic"	"transcriptomic"	"transcriptomic"	"transcriptomic"	"transcriptomic"	"transcriptomic"	"transcriptomic"	"transcriptomic"	"transcriptomic"	"transcriptomic"	"transcriptomic"	"transcriptomic"	"transcriptomic"	"transcriptomic"	"transcriptomic"	"transcriptomic"	"transcriptomic"	"transcriptomic"	"transcriptomic"	"transcriptomic"	"transcriptomic"	"transcriptomic"
!Sample_library_strategy	"RNA-Seq"	"RNA-Seq"	"RNA-Seq"	"RNA-Seq"	"RNA-Seq"	"RNA-Seq"	"RNA-Seq"	"RNA-Seq"	"RNA-Seq"	"RNA-Seq"	"RNA-Seq"	"RNA-Seq"	"RNA-Seq"	"RNA-Seq"	"RNA-Seq"	"RNA-Seq"	"RNA-Seq"	"RNA-Seq"	"RNA-Seq"	"RNA-Seq"	"RNA-Seq"	"RNA-Seq"	"RNA-Seq"	"RNA-Seq"	"RNA-Seq"	"RNA-Seq"	"RNA-Seq"	"RNA-Seq"	"RNA-Seq"
!Sample_relation	"BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN08513906"	"BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN08513908"	"BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN08513907"	"BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN08513909"	"BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN08513910"	"BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN08513912"	"BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN08513911"	"BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN08513913"	"BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN08514192"	"BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN08514191"	"BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN08514190"	"BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN08514189"	"BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN08514187"	"BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN08514186"	"BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN08514207"	"BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN08514206"	"BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN08514205"	"BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN08514204"	"BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN08514203"	"BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN08514202"	"BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN08514201"	"BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN08514200"	"BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN08514199"	"BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN08514198"	"BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN08514197"	"BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN08514196"	"BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN08514195"	"BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN08514194"	"BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN08514193"
!Sample_relation	"SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX3678118"	"SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX3678119"	"SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX3678120"	"SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX3678121"	"SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX3678122"	"SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX3678123"	"SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX3678124"	"SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX3678125"	"SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX3678126"	"SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX3678127"	"SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX3678128"	"SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX3678129"	"SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX3678130"	"SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX3678131"	"SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX3678132"	"SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX3678133"	"SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX3678134"	"SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX3678135"	"SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX3678136"	"SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX3678137"	"SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX3678138"	"SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX3678139"	"SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX3678140"	"SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX3678141"	"SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX3678142"	"SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX3678143"	"SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX3678144"	"SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX3678145"	"SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX3678146"
!Sample_supplementary_file_1	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"
!series_matrix_table_begin
"ID_REF"	"GSM2991062"	"GSM2991063"	"GSM2991064"	"GSM2991065"	"GSM2991066"	"GSM2991067"	"GSM2991068"	"GSM2991069"	"GSM2991070"	"GSM2991071"	"GSM2991072"	"GSM2991073"	"GSM2991074"	"GSM2991075"	"GSM2991076"	"GSM2991077"	"GSM2991078"	"GSM2991079"	"GSM2991080"	"GSM2991081"	"GSM2991082"	"GSM2991083"	"GSM2991084"	"GSM2991085"	"GSM2991086"	"GSM2991087"	"GSM2991088"	"GSM2991089"	"GSM2991090"
!series_matrix_table_end
